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A B S T R A C T
Background
This review updates the original review, ’Pharmacological treatments for fatigue associated with palliative care’ and also incorporates
the review ’Drug therapy for the management of cancer-related fatigue’.
In healthy individuals, fatigue is a protective response to physical or mental stress, often relieved by rest. By contrast, in palliative care
patients’ fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life.
Fatigue frequently occurs in patients with advanced disease (e.g. cancer-related fatigue) and modalities used to treat cancer can often
contribute. Further complicating issues are the multidimensionality, subjective nature and lack of a consensus definition of fatigue.
The pathophysiology is not fully understood and evidence-based treatment approaches are needed.
Objectives
To evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of
disease, including patients with cancer and other chronic diseases.
Search methods
For this update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PsycINFO and EMBASE,
and a selection of cancer journals up to 28 April 2014. We searched the references of identified articles and contacted authors to obtain
unreported data. To validate the search strategy we selected sentinel references.
Selection criteria
We considered randomised controlled trials (RCTs) concerning adult palliative care with a focus on pharmacological treatment of
fatigue compared to placebo, application of two drugs, usual care or a non-pharmacological intervention. The primary outcome had
to be non-specific fatigue (or related terms such as asthenia). We did not include studies on fatigue related to antineoplastic treatment
(e.g. chemotherapy, radiotherapy, surgical intervention). We also included secondary outcomes that were assessed in fatigue-related
studies (e.g. exhaustion, tiredness).
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Data collection and analysis
Two review authors (MM and MC) independently assessed trial quality and extracted data. We screened the search results and included
studies if they met the selection criteria. If we identified two or more studies that investigated a specific drug with the same dose in
a population with the same disease and using the same assessment instrument or scale, we conducted meta-analysis. In addition, we
compared the type of drug investigated in specific populations, as well as the frequent adverse effects of fatigue treatment, by creating
overview tables.
Main results
For this update, we screened 1645 publications of which 45 met the inclusion criteria (20 additional studies to the previous reviews).
In total, we analysed data from 18 drugs and 4696 participants. There was a very high degree of statistical and clinical heterogeneity in
the trials and we discuss the reasons for this in the review. There were some sources of potential bias in the included studies, including
a lack of description of the methods of blinding and allocation concealment, and the small size of the study populations. We included
studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in
patients suffering from advanced cancer and fatigue in meta-analysis. Treatment results pointed to weak and inconclusive evidence
for the efficacy of amantadine, pemoline and modafinil in multiple sclerosis and for carnitine and donepezil in cancer-related fatigue.
Methylphenidate and pemoline seem to be effective in patients with HIV, but this is based only on one study per intervention, with
only a moderate number of participants in each study. Meta-analysis shows an estimated superior effect for methylphenidate in cancer-
related fatigue (standardised mean difference (SMD) 0.49, 95% confidence interval (CI) 0.15 to 0.83). Therapeutic effects could not be
described for dexamphetamine, paroxetine or testosterone. There were a variety of results for the secondary outcomes in some studies.
Most studies had low participant numbers and were heterogeneous. In general, adverse reactions were mild and had little or no impact.
Authors’ conclusions
Based on limited evidence, we cannot recommend a specific drug for the treatment of fatigue in palliative care patients. Fatigue research
in palliative care seems to focus on modafinil and methylphenidate, which may be beneficial for the treatment of fatigue associated
with palliative care although further research about their efficacy is needed. Dexamethasone, methylprednisolone, acetylsalicylic acid,
armodafinil, amantadine and L-carnitine should be further examined. Consensus is needed regarding fatigue outcome parameters for
clinical trials.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological treatments for fatigue associated with advanced disease
In an advanced disease such as cancer, fatigue can be described as tiredness, weakness or lack of energy. Fatigue can affect daily activity
and quality of life, and it is frequently reported by palliative care patients. The underlying causes of fatigue are not very well understood
and fatigue is difficult to treat.
We searched the literature in April 2014 and found 45 randomised controlled trials for this update of the review. We analysed data
from 4696 participants who received treatment for their fatigue. The trials dealt with neurological diseases (such as multiple sclerosis
(753 participants), post-polio syndrome (58) and Parkinson’s disease (19)), different types of cancer (3223), HIV/AIDS (514), end-
stage renal disease (56), multi-type advanced disease in hospice patients (30), amyotrophic lateral sclerosis (28) and end-stage chronic
lung disease (15).
There was weak evidence for the efficacy of amantadine, pemoline and modafinil in reducing fatigue in patients with multiple sclerosis.
There was also weak evidence for the efficacy of carnitine and donepezil for cancer-related fatigue. One small trial showed that people
with HIV/AIDS and fatigue seemed to benefit from treatment with methylphenidate or pemoline. There was some low-quality evidence
from small trials that methylphenidate, a stimulant drug that improves concentration, is effective for the management of cancer-related
fatigue. There was no information about dexamphetamine, paroxetine or testosterone.
Previous studies have shown that erythropoietin and darbepoetin, drugs that improve anaemia (lack of iron), are also effective for
cancer-related fatigue. However, due to safety concerns and side effects shown by more recent studies, erythropoietin and darbepoetin
should no longer be used. Therefore, we excluded these drugs from this review update.
Overall, most side effects of the investigated drugs seemed to be mild.
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Based on limited evidence from small studies, the evidence does not support the use of a specific drug for the treatment of fatigue in
palliative care. Future trials should measure fatigue in advanced disease using comparable and standardised measures.
B A C K G R O U N D
This review is not only an update of a previously published review
in theCochraneDatabase of SystematicReviews (Peuckmann-Post
2011). We have also conducted it with a new search strategy to
incorporate another review on drug therapy for the management
of cancer-related fatigue (Minton 2010), in order to increase its
scope.
In healthy individuals, fatigue serves as a protective response to
physical or mental stress. By contrast, in patients with chronic dis-
ease, fatigue can be severely debilitating and thereby have an im-
pact on quality of life and daily activities (Morrow 2005). Fatigue
is a common symptom in palliative care patients and virtually ev-
ery intervention used to treat cancer, as well as the primary disease
itself, may cause or contribute to fatigue. In a study of 1000 pa-
tients in an American palliative care programme, fatigue, weakness
and lack of energy were three of the five most frequently reported
symptoms with a prevalence of 84%, 66% and 61%, respectively
(Walsh 2000). Fatigue is also commonly reported in non-cancer
patients with progressive life-threatening diseases, such asmultiple
sclerosis and amyotrophic lateral sclerosis (progressive degenera-
tion of motor neurons leading to cumulative paralysis), as well as
chronic heart, kidney or lung diseases (Jhamb 2013; Tang 2010).
More than half of patients with multiple sclerosis describe fatigue
as one of their most troubling symptoms (Bakshi 2003; Krupp
2003;NMSS2002). Fatigue has also been reported by themajority
of patients with chronic obstructive pulmonary disease (COPD)
(Elkington 2005; Stridsman 2014; Trendall 2001) and heart fail-
ure (Goodlin 2005). Approximately half of HIV patients suffer
from fatigue (Breitbart 1998; Norval 2004). High levels of tumour
necrosis factor (TNF) and interleukin-1 fromHIV infections may
cause fatigue (Darko 1995). Cancer-related fatigue is one of the
most common symptoms experienced by cancer patients (Cuhls
2014; Morrow 2003). It can be problematic at the time of diag-
nosis, during and after treatment and in patients with advanced
disease (Cuhls 2014; Morrow 2003). Most studies have reported
prevalence figures in excess of 60% (Stone 2002). The subjective
sensations attributed to cancer-related fatigue are characterised by
a pervasive and persistent sense of tiredness, which is not relieved
by sleep or rest. Several drugs, such as the new anti-neoplastic ther-
apies, may be associated with novel causes of secondary fatigue.
Drugs regularly used in palliative care have sedative properties,
for example opioid analgesics, benzodiazepines, antidepressants or
anticonvulsants can cause fatigue load (EAPC 2008).
Description of the condition
The pathophysiology of fatigue in palliative care patients is not
fully understood. ’Primary fatigue’ has been said to be related to
the high cytokine load (release of high amounts of cytokines from
the tumour or antineoplastic therapy). Associated disease-related
symptoms, such as sleep disturbances, infections, malnutrition,
hypothyroidism and anaemia, may also account for fatigue and
may be termed ’secondary fatigue’. Synonyms for fatigue are as-
thenia, neuromuscular weakness and tiredness. There seems to be
a considerable overlap between fatigue and depression. Weakness
and tiredness are among the predominant symptoms of depres-
sion and feeling depressed is often part of the affective dimension
of fatigue. However, there are some symptoms that are associated
with depression (such as sustained feelings of worthlessness, recur-
rent thoughts of death) and some symptoms that are considered
specific to fatigue (such as post-exertional malaise).
Different definitions have been proposed for fatigue. In partner-
ship with the American Cancer Society, the National Compre-
hensive Cancer Network (NCCN) defines cancer-related fatigue
as “a distressing persistent, subjective sense of tiredness or exhaus-
tion related to cancer or cancer treatment that is not proportional
to recent activity and interferes with usual functioning” (NCCN
2014). A similar definition has been used for multiple sclerosis: “a
subjective lack of physical and/or mental energy that is perceived
by the individual or caregiver to interfere with usual and desired
activities” (NMSS 2002). The Fatigue Coalition has suggested the
use of the International Classification of Diseases - 10 (ICD-10)
criteria for the definition of cancer-related fatigue, which is “sig-
nificant fatigue, diminished energy or an increased need to rest,
disproportionate to any recent change in activity level” and has to
be present every day or nearly every day for two consecutive weeks
out of the lastmonth (Cella 2001). Five out of 10 additional symp-
toms, such as generalised weakness, diminished concentration or
unrestorative sleep, are required for the diagnosis. However, the
symptom thresholds and time span have been chosen arbitrarily
(Cella 1998), and this has been criticised. Considering the lack
of an internationally acknowledged definition, we identified and
chose the following working definition for this review: “Fatigue is
a subjective feeling of tiredness, weakness, or lack of energy”; this
definition has been suggested by an expert working group of the
European Association of Palliative Care (EAPC 2008).
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Description of the intervention
Assessment of fatigue will depend on subjective self evaluation
by the patient, substituted by caregiver or medical staff estima-
tions only where self assessment is not possible. Single-item scales
(e.g. ’do you get tired for no reason?’) have been proposed and a
multitude of checklists and questionnaires with multiple dimen-
sions (such as physical, affective and cognitive) have been validated
(Dittner 2004).
Lack of consensus on the definition of fatigue and its subjec-
tive and multidimensional nature, as well as culture and language
differences, have challenged research approaches to fatigue. Fur-
ther, standard research studies, such as double-blinded randomised
controlled trials (RCTs), can often not be performed in this de-
bilitated patient population due to fluctuating symptom inten-
sity, declining performance status, rapid disease trajectories and
short prognosis, resulting in weak evidence for treatment strate-
gies. Several instruments exist to evaluate fatigue, but no consen-
sus on significant cut-off levels has yet been achieved to establish a
model of clinicallymeaningful improvement of fatigue.Only a few
scales and instruments have been evaluated for different languages
(Cantarero-Villanueva 2014; Kummer 2011). A structured ap-
proach with assessment and treatment steps is lacking. As a result,
fatigue continues to be underestimated and undertreated. Con-
sequently, a structured approach, including treatment options, is
needed.
Treatment options for fatigue should address the causal mecha-
nism if possible. However, the underlying mechanism of action
is often not known and may be complex. Most patients will re-
quire symptomatic treatment of fatigue with pharmacological and
non-pharmacological therapies. Non-pharmacological treatment
options include patient education with provision of information
on fatigue and its treatment, keeping a diary, energy expenditure
planning and physical exercise (review in Mock 2004; NCCN
2014; Schmitz 2005). Recent studies support the use of resistance
training or ’anabolic’ exercise (Galvao 2005). Most patients will
try to counteract exhaustion and fatigue with prolonged periods of
rest (Richardson 1997).However, rest will often not restore energy
and persistent reduction of physical activity may even promote
fatigue (Evans 2007).
Pharmacological treatment of fatigue may work through inter-
action with cytokine load and the patient’s host reaction to the
underlying disease, restoring peripheral energy depletion, or by
treating metabolic disorders and supplementing other apparent
physiological deficiencies such as decreased haemoglobin concen-
tration (Morrow 2005). There is a growing body of evidence that
gives examples of effective pharmacological treatments for fatigue
(Barak 2014; Lawrence 2004; Morrow 2005; Patrick 2004; Rao
2004; Rosenberg 2005; Wagner 2004; Yennurajalingam 2013;
Zifko 2004). Drug treatment for non-specific fatigue will be re-
quired by many patients in addition to specific measures against
deficiencies or comorbid conditions. Concerning drug-induced
fatigue, for example with opioid treatment, symptomatic phar-
macological treatment of fatigue may functionally counteract this
adverse effect, probably by enhancing excitatory mechanisms as
observed following treatment with amphetamines (Sood 2006).
Why it is important to do this review
The latest systematic review about pharmacological treatments for
fatigue associated with palliative care was published several years
ago (Peuckmann-Post 2011). Other systematic reviews have cov-
ered the use of particular drugs for fatigue in multiple sclerosis,
such as amantadine (Pucci 2007), and carnitine (Tejani 2012).
Treatment of fatigue in cancer patients, including erythropoietic
agents, was the subject of another Cochrane review with meta-
analysis (Minton 2010). In contrast to this meta-analysis our re-
view aims to cover a broader scope of palliative care patients with
cancer and non-cancer diseases, but it is restricted to advanced-
stage diseases. We have incorporated the main topic of Minton
2010 into this review, so that cancer-related fatigue will be re-
flected.
O B J E C T I V E S
To evaluate the efficacy of pharmacological treatments for fatigue
in palliative care, with a focus on patients at an advanced stage of
disease, including patients with cancer and other chronic diseases.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included randomised controlled trials (RCTs). We con-
sidered full reports concerning fatigue in palliative care with a fo-
cus on pharmacological treatment. The primary outcome of these
studies had to be fatigue (or related terms such as asthenia). We
searched for diseases requiring palliative care or diseases at an ad-
vanced, life-threatening stage.
Types of participants
• Age 18 years or more.
• Participants of both sexes.
• Palliative care patients with fatigue, i.e. patients with an
incurable disease (terminal illness) such as advanced cancer,
HIV/AIDS, multiple sclerosis, amyotrophic lateral sclerosis, or
cardiac, lung or kidney failure. Participants could receive
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anticancer treatment. We considered terminal illness to be when
the estimated life expectancy is six months or less, under the
assumption that the disease will run its normal course.
Types of interventions
• Identified studies had to evaluate and report the effect of
pharmacological treatment on fatigue with the following drugs:
psychostimulants (amphetamines, modafinil, armodafinil,
methylphenidate, pemoline), amantadine, corticosteroids
(dexamethasone, prednisone, methylprednisolone), donepezil,
antidepressants such as selective serotonin reuptake inhibitors
(SSRIs; paroxetine), acetylsalicylic acid, megestrol acetate,
alfacalcidol and acetyl-L-carnitine.
• If we identified further agents used for the treatment of
unspecific fatigue, we added these studies.
• Studies should compare fatigue with drug treatment versus
no drug treatment or versus alternative drug treatment, or both.
• We did not include studies on the pharmacological
treatment of fatigue with a primary target of clinical conditions
such as depression or anxiety.
• We included antidepressants only if used for the treatment
of fatigue as the primary outcome.
• We did not focus on physiological deficiencies such as lack
of haemoglobin (erythropoietic agents, blood transfusion), nor
did we focus on drugs targeting specific cytokines, e.g. for
reduction of tumour necrosis factor alpha, as these treatments
target specific aetiologies of fatigue. Erythropoietic agents have
been covered in the review by Minton et al (Minton 2010).
• We did not include studies comparing different types of
cancer-modifying treatment and the effect on prognosis and
quality of life. We also excluded those studies which did not
focus on pharmacological treatment.
• We did not include studies on fatigue related to
antineoplastic treatment (e.g. chemotherapy, radiotherapy,
surgical intervention).
Types of outcome measures
Primary outcomes
1. Patient-reported fatigue (self reported measures or validated
self assessment tools, or both), substituted by caregiver or
medical staff estimations only where self assessment was not
possible, and measurement using reliable and valid assessment
instruments (single-item scales or questionnaire instruments).
2. Improvement of fatigue. Since no gold standard for the
treatment or improvement of fatigue exists, we suggested an
improvement of fatigue intensity by 33% related to the range of
the assessment instrument to be clinically significant. This is
congruent with the improvement of pain intensity, where a 33%
reduction has been described as significant from the patient’s
point of view (Farrar 2003).
Secondary outcomes
1. Asthenia (lack of strength) assessed with quality of life
instruments such as SF-36.
2. Weakness assessed with scales, e.g. visual analogue scale -
fatigue (VAS-F).
3. Tiredness, sedation assessed with scales such as the Chalder
Fatigue Scale (CFS) or Center for Epidemiologic Studies
Depression (CESD) scale.
4. Exhaustion, assessed with e.g. the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC-QLQ-C30).
5. Treatment-related burden: adverse events (including cardiac
arrhythmia and thromboembolic events), morbidity or mortality
measured as percentages of participants, adverse events also
measured as a percentage of participants with moderate/severe
intensity, probability of a causal relationship between adverse
events and treatment.
Search methods for identification of studies
For this update, we have re-engineered the search strategy (filter) of
the previous review (Peuckmann-Post 2011) to facilitate the com-
bination with another review (Minton 2010). To identify stud-
ies for inclusion in this updated review, we developed a detailed
search strategy for each electronic database and other resources. To
validate the search strategy, we selected sentinel references. There
were no language or date restrictions.
Electronic searches
We searched the following electronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue 3); search strategy as detailed in
Appendix 1;
• MEDLINE (OVID) from inception to 28 April 2014;
search strategy as detailed in Appendix 2;
• EMBASE (OVID) from inception to 28 April 2014; search
strategy as detailed in Appendix 3;
• PsycINFO (OVID) from inception to 28 April 2014;
search strategy as detailed in Appendix 4.
Searching other resources
We screened the reference lists of identified articles for additional
studies.
We handsearched standard textbooks on palliative medicine (Ox-
ford Textbook of Palliative Medicine, Oxford; Textbook of Nursing,
Textbook of Palliative Medicine).
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We also obtained unpublished literature through searches of con-
ference proceedings, such as all meetings of the American Society
of Clinical Oncology (ASCO) from 2000 to 2013, the 2013 meet-
ing of the European Cancer Congress (ECCO) and the European
Association of Palliative Care (EAPC) databases of all abstracts
registered online from 2003 to 2014.
We contacted experts in the field of fatigue in palliative care in
order to identify research awaiting publication.
Data collection and analysis
Selection of studies
We retrieved in full all studies in which the abstract refers to drug
intervention aimed at treating fatigue in palliative care. Eligible
studies had to define fatigue as a primary outcome and at least one
treatment arm had to be a drug intervention.
Data extraction and management
We organised data using the software Review Manager 5.3
(RevMan 2014). Two review authors extracted data (MM and
MC) using a standard data extraction form. Two authors (MM
and MC) reviewed the data from the included studies and two
other authors (LR and HC) cross-checked a sub-sample. We re-
solved disagreement by consensus.
Assessment of risk of bias in included studies
Two authors (MM and MC) independently assessed risk of bias
for each study, using the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) and
adapted from those used by the Cochrane Pregnancy and Child-
birth Group, with any disagreements resolved by discussion or by
involving other review authors (LR, HC). We assessed the follow-
ing for each study:
Random sequence generation (checking for possible selection
bias)
We assessed the method used to generate the allocation sequence
as: low risk of bias (any truly random process, e.g. random number
table; computer random number generator); unclear risk of bias
(methodused to generate sequence not clearly stated).We carefully
considered studies using a non-random process.
Allocation concealment (checking for possible selection bias)
The method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could have
been foreseen in advance of, or during recruitment, or changed
after assignment. We assessed the methods as: low risk of bias
(e.g. telephone or central randomisation; consecutively numbered,
sealed, opaque envelopes); unclear risk of bias (method not clearly
stated). We excluded studies that did not conceal allocation (e.g.
open list).
Blinding of outcome assessment (checking for possible detection
bias)
We assessed the methods used to blind study participants and
outcome assessors from the knowledge of which intervention a
participant received. We assessed the methods as: low risk of bias
(study states that it was blinded and describes the method used to
achieve blinding, e.g. identical tablets, matched in appearance and
smell); unclear risk of bias (study states that it was blinded but does
not provide an adequate description of how this was achieved).
We excluded studies that were not double-blind.
Incomplete outcome data (checking for possible attrition bias
due to the amount, nature and handling of incomplete outcome
data)
We assessed themethods used to deal with incomplete data as: low
risk (less than 10% of participants did not complete the study and/
or used ’baseline observation carried forward’ analysis); unclear
risk of bias (used ’last observation carried forward’ analysis); high
risk of bias (used ’completer’ analysis).
Size of study (checking for possible biases confounded by small
size)
We assessed studies as being at low risk of bias (200 participants
or more per treatment arm); unclear risk of bias (50 to 199 par-
ticipants per treatment arm); high risk of bias (fewer than 50 par-
ticipants per treatment arm).
Measures of treatment effect
We intended to evaluate the methodological quality of each study,
as well as the evidence for drug interventions to treat fatigue, us-
ing the GRADE system (Atkins 2004). We aimed to further eval-
uate studies by setting ’clinically relevant improvement’ equal to
improvement by one-third compared to baseline fatigue intensity
and to calculate a number needed to treat to benefit (NNTB) ac-
cordingly (NNTB to achieve at least a 33% improvement of fa-
tigue intensity compared to the baseline fatigue level). We aimed
to calculate numbers needed to treat to harm (NNTH) for adverse
events with moderate or severe intensity.
If calculation of the NNTB was not possible, ’clinically relevant
improvement’ would be defined as a change of 5% or more of
the primary outcome instrument used in the study. This would
be in accordance with the study of Cella et al, identifying changes
between 3.7% and 5.8% of the aggregated summary scores as
’clinically important’ (Cella 2002).
In addition, for each identified study, we aimed to extract:
• number of participants in each arm;
• type of control group;
• quality of the study (randomisation, blinding, per protocol
analysis, intention-to-treat (ITT) analysis, number of
withdrawals described);
• demographic characteristics, including age and sex;
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• type of primary disease;
• type and stage of treatment, if applicable;
• type of drug used for the pharmacological intervention;
• duration and pharmacological regimen of drug treatment
with the drug of interest;
• outcome measures employed, including means and
standard deviations.
We documented outcomes of fatigue in different ways. If we iden-
tified two or more studies that investigated a specific drug with
the same dose in a population with the same disease and same
assessment instrument or scale, we conducted a meta-analysis. We
aimed to calculate the standardised mean difference (SMD) in fa-
tigue intensity, stating whether it had reached a potentially signif-
icant cut-off level and we aimed to compare these data to other
interventions and control groups, wherever available. Wherever
appropriate, we calculated standard deviations (SD) for standard-
isation of the mean difference (MD) as the square root of the aver-
age of the variances before and after the intervention. Similarly, if
only 95% confidence intervals (CI) were described, we converted
these values to SDs by dividing the difference of the CI and mean
by a factor of 1.96.
A NNTB of 50% reduction has been suggested as significant for
an exercise intervention in cancer-related fatigue (Cramp 2012).
Since only limited information on the cut-off level for clinically
significant fatigue has been identified to date, we suggested a 33%
improvement as a basis for NNTB calculation, since palliative
care patients are more debilitated than the population that was
examined in the Cramp 2012 review. A 33% reduction of pain
intensity has been described as significant from the patients’ point
of view in studies on breakthrough pain management (Farrar
2003).
Unit of analysis issues
The unit of randomisation was the individual patient.
Dealing with missing data
We contacted the original investigators to requestmissing data.We
used intention-to-treat (ITT) analysis where possible. The ITT
population consisted of participants who were randomised, took
the assigned study medication and provided at least one post-base-
line assessment. We assigned missing participants zero improve-
ment (baseline observation carried forward (BOCF), where this
could be done. We were aware that imputation methods might
be problematic and examined trial reports for information about
them.
Assessment of heterogeneity
We explored the homogeneity of the results of the various end-
points of interest using I² statistic values.We regarded heterogene-
ity in the results as a result of many potential factors (postulated a
priori), and we made efforts to identify subgroups for sensitivity
analysis. We undertook meta-analysis. As a result of high statisti-
cal heterogeneity, we used a random-effects model for analysis. If
possible, and where applicable, we conducted subgroup analyses
to explore possible sources of heterogeneity due to participants,
interventions or methods.
Potential sources of heterogeneity:
• disease entities;
• performance status;
• quality of studies;
• medication dose and frequency;
• duration of treatment;
• duration of follow-up;
• rate of attrition;
• outcome measures used;
• case mix/stage of disease accessed.
Assessment of reporting biases
To decrease the influence of potential publication bias, we con-
ductedmanual and electronic searches ofmultiple databases, with-
out imposing any language restriction, to check for published or
registered study protocols and to verify whether results from these
studies have been published subsequently. We contacted the trial
authors by email if there was insufficient information to assess re-
porting bias. We also contacted the authors to clarify information,
if there were mismatches between study protocols and reports.
Data synthesis
For data synthesis, we used Review Manager 5.3 (RevMan 2014),
as provided by The Cochrane Collaboration. We grouped meta-
analyses of the data from all included studies using the I² statistic.
If the I² value was greater than or equal to 50% (substantial or
considerable heterogeneity), we used a random-effects model. If
the I² value was less than 50%, we used a fixed-effect model. We
reported the results from both models.
Subgroup analysis and investigation of heterogeneity
We intended to conduct a subgroup analysis where data were avail-
able. We performed separate analysis for different kinds of pri-
mary diseases (such as cancer or multiple sclerosis). If it was not
possible to carry out a quantitative analysis, then we considered a
qualitative review and a synthesis of the study results.
In this review, we performed subgroup analyses for the following:
• different types of drug treatment;
• different types of disease;
• different types of assessment tools.
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Sensitivity analysis
We carried out sensitivity analysis for the primary outcome mea-
surements in order to explore effect size differences and the ro-
bustness of our conclusions. We planned sensitivity analysis de-
termined a priori based on:
• studies without study limitations with regard to a)
allocation concealment; b) blinding of participants and
investigators; c) recruitment bias; d) baseline imbalance between
groups; e) loss to follow-up of clusters; f ) adequate analysis;
• method of analysis: results of a) studies using number of
patients analysed; b) studies using number of patients
randomised.
R E S U L T S
Description of studies
This review updates and combines two existing reviews: Minton
2010 and Peuckmann-Post 2011. The previous review, Minton
2010, found 31 studies involving 7140 participants and the re-
view Peuckmann-Post 2011 identified 22 eligible studies with a
total of 1632 participants. We used a new search strategy for this
update, providing 1645 results that we screened. Most of these
articles did not focus on fatigue as a primary outcome but on the
drug treatment of underlying disease. The updated search strat-
egy identified 20 additional studies suitable for inclusion. Only
seven of the studies included in the Minton 2010 review, but all
22 of the previously included studies in Peuckmann-Post 2011,
matched our results. The small number of matched study results
between this updated review and the Minton 2010 review is due
to the fact that we did not include haemopoietic growth factors
in our search strategy. Safety concerns have been raised regard-
ing the erythropoiesis-stimulating agents (erythropoietin and dar-
bepoetin) since the last publication of the original review, there-
fore the use of these drugs is no longer recommended in practice
(Bennet 2008; Bohlius 2009; EAPC 2008; Glaspy 2009; Glaspy
2010; Tonelli 2009). We found and removed 186 duplicate stud-
ies (Figure 1). We checked the retrieved articles against the inclu-
sion criteria and included 45 studies. We identified no additional
unpublished data by contacting experts in palliative care and we
retrieved no additional studies from the handsearched reference
lists or abstract databases on the Internet.
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Figure 1. Study flow diagram.
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Meta-analysis of data was possible for modafinil in multiple scle-
rosis (two studies, n = 136 participants), pemoline in multiple
sclerosis (two studies, n = 103 participants) and methylphenidate
in cancer patients (two studies, n = 146 participants).
See also Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
We screened 1645 publications, of which 45 met the inclusion
criteria and we included them for further analysis. In total, we
analysed data from 18 drugs and 4696 participants. We used stud-
ies investigating pemoline andmodafinil in participants with mul-
tiple sclerosis-associated fatigue and methylphenidate in partici-
pants suffering from cancer and fatigue for meta-analysis.
Included studies
See Characteristics of included studies table.
The 45 studies retrieved for the review yielded a broad spectrum
of diseases associated with fatigue as well as different drugs (Table
1).
Fatigue was typically examined in association with diseases as fol-
lows: multiple sclerosis (13 studies), HIV/AIDS (including HIV
and hypogonadism) (seven studies), cancer (including advanced
cancer, cancer of different origins and brain tumours) (18 stud-
ies), post-polio (two studies), Parkinson’s disease (one study), end-
stage renal disease (ESRD) (one study), amyotrophic lateral scle-
rosis (one study), multi-type advanced disease (hospice patients)
(one study) and end-stage COPD (one study).
Drug studiedwere as follows: amantadine (nine studies), pemoline
(three studies), megestrol acetate (one study), methylphenidate
(seven studies), dexamphetamine (two studies), paroxetine (two
studies), acetyl-L-carnitine (four studies), testosterone (three stud-
ies), donepezil (one study), modafinil (eight studies), dexam-
ethasone (one study), fluoxetine (two studies), alfacalcidol (one
study), armodafinil (one study), mistletoe extract PS76A2 (one
study), methylprednisolone (one study), medroxyprogesterone ac-
etate (one study) and acetylsalicylic acid (two studies).
In contrast, Morrow 2003 examined fatigue related to both cancer
and treatment. Wagner 2000 and Rabkin 2004 examined fatigue
in patients with depression, where it may be difficult to differen-
tiate whether fatigue was primary or secondary to depression.
Most studies reported data from a relatively small number of par-
ticipants: for the 45 studies included, only 17 reported a partic-
ipant number greater than 100. Participant numbers, including
controls, varied from six (Rosenberg 1988) to 544 (Jean-Pierre
2010). The total number of participants who completed the stud-
ies included in our analysis was 4696. Issues associated with in-
conclusive findings were as follows: differences in data reporting,
heterogenous populations, inconsistent symptom assessment (the
use of instrument differed greatly) and lack of a consistent defi-
nition for a clinically significant reduction in fatigue. Therefore
it was not possible to calculate the NNTB or NNTH, nor could
we calculate a 5% reduction of fatigue as consistently as intended
and described above.
Some trials in this review only used single-item fatigue assessment.
However, it is now considered by European palliative care experts
that a single-item tool could be as good as a comprehensive as-
sessment. Single-item assessments of fatigue may have drawbacks,
but more complex assessment methods may also be problematic
in patients with advanced disease as they require some cognitive
capacity, which is often lacking in a fatigue patient group. Ex-
cluding these studies would cause a new bias, as would excluding
studies in end-of-life care and focused on patients in oncological
care. Hence, we included and analysed these trials in our review.
Excluded studies
The previous review, Peuckmann-Post 2011, excluded 23 stud-
ies and the review by Minton 2010 excluded 14 studies. For this
update, we had to exclude 49 studies in the final selection pro-
cess after reading the manuscript. Reasons for exclusion were typ-
ically a lack of inclusion criteria match (e.g. fatigue defined as a
secondary outcome; case series; not a RCT), investigation of fa-
tigue attributed to narcotic-induced sedation, data were a subset
of another study which had been already included in the analysis,
or data were not from patients with advanced disease. We listed
these studies with the reason for exclusion in the Characteristics
of excluded studies table.
Risk of bias in included studies
Some studies specifically described the randomisation and blind-
ing procedure and we therefore considered them to have a mini-
mal risk of bias concerning allocation concealment (e.g. Cruciani
2012; Roth 2010). However, some studies did not specify these
procedures, but used the terminology “double-blind, randomised
controlled trial”, allowing the assumption of a low risk of bias (e.g.
Barak 2014; Lange 2009).
Considering the relatively small number of participants in most of
the included studies, as well as the variety of instruments used, the
results have to be interpreted with caution. The small numbers of
participants may be a reason for a lack of stratification (for exam-
ple, for relevant health conditions such as depression or sociode-
mographic data such as age or sex), which may alter the outcome
as demonstrated by some investigators (Eriksen 2003; Tomassini
2004).
We assessed each study using the Cochrane ’Risk of bias’ tool.
The findings are presented in the ’Risk of bias’ graph (Figure 2),
which reviews the authors’ judgements about each risk of bias item
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shown as percentages across all included studies, and the ’Risk of
bias’ summary (Figure 3), which reviews the authors’ judgements
about each risk of bias item for each included study.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about risk of bias items for each included
study.
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Allocation
All studies reported randomisation, but no more than 23 in-
cluded a proper description of the methods used (Breitbart
2001; Bruera 2006; Bruera 2007; Cruciani 2009; Cruciani 2012;
Fisch 2003; Jean-Pierre 2010; Kerr 2012; Knapp 2008; Moraska
2010; Morrow 2003; Rabkin 2000; Rabkin 2004; Rabkin 2009;
Rabkin 2010; Rabkin 2011; Semiglazov 2006; Shaygannejad
2012; Simons 1996; Spathis 2014; Vasconcelos 2007; Westman
1999; Wingerchuk 2005). Only nine described the method used
to conceal the allocation appropriately (Bruera 2006; Bruera
2007; Lacasse 2004; Moraska 2010; Rabkin 2009; Semiglazov
2006; Shaygannejad 2012; Spathis 2014; Vasconcelos 2007;
Wingerchuk 2005).
Blinding
Twenty studies were double-blind (Ashtari 2009; Auret 2009;
Breitbart 2001; Butler 2007; Cruciani 2009; Cruciani 2012;
Krupp 1995; Lou 2009; Morrow 2003; Rabkin 2000; Rabkin
2004; Rabkin 2009; Rabkin 2010; Rabkin 2011; Roth 2010;
Semiglazov 2006; Spathis 2014; Vasconcelos 2007; Westman
1999; Wingerchuk 2005). The remainder did not provide suffi-
cient information to assess risk of bias (unclear risk).
Incomplete outcome data
There were only four studies lacking sufficient information to
assess risk (unclear risk of bias) (Butler 2007; Krupp 1995;
Weinshenker 1992; Yennurajalingam 2013). We judged the re-
maining 41 studies to meet the criteria for low risk of bias.
Other potential sources of bias
Treatment group size was an issue. Small studies are thought to
be at increased risk of bias, probably because the conduct of small
studies is more likely to be less rigorous, allowing critical criteria
to be compromised. Only two of the treatment groups in this
review were large enough to give a low risk of bias (Jean-Pierre
2010; Morrow 2003). We judged 14 studies to have an unclear
risk (Barak 2014; Bruera 2006; Bruera 2007; Canadian MSRG
1987; Cruciani 2012; Della Cuna 1989; Fisch 2003; Moraska
2010; Rabkin 2010; Semiglazov 2006; Simons 1996; Spathis
2014; Stankoff 2005; Westman 1999). We judged the remainder
to have a high risk of bias due to size.
Effects of interventions
Most studies reported some benefit of the active treatment. How-
ever, there was often a substantial and very similar placebo ef-
fect. Further, reviewing only fatigue-specific instruments (e.g. the
Chalder Fatigue Scale (CFS), Fatigue Severity Scale (FSS), visual
analogue scale (VAS) for fatigue), these benefits could not be con-
firmed in many cases. See also: Types of outcome measures. In
general, adverse reactions were mild and had little or no impact
(Table 2).
Acetyl-L-carnitine versus placebo
Acetyl-L-carnitine was compared with placebo in a study of 29
participants with cancer-related fatigue, with no significant effect
(Cruciani 2009). FACT-fatigue mean scores were 15.7 (SD 10.6)
at baseline and 22.2 (10.4) at week two (P value = 0.97). A recent
study of 209 participants did not show statistically significant im-
provement in fatigue compared to placebo (Cruciani 2012). The
primary outcome, fatigue, measured using the Brief Fatigue In-
ventory (BFI), improved in both arms in comparison to baseline
(L-carnitine: -0.96, 95% confidence interval (CI) -1.32 to -0.60;
placebo: -1.11, 95%CI -1.44 to -0.78). There were no statistically
significant differences between the arms (P value = 0.57), while
the secondary outcomes, including fatigue measured on the Func-
tional Assessment for Chronic Illness Therapy - Fatigue (FACIT-
F) scale, did not show a significant difference between arms, with
a change in mean of 31.4 (standard deviation (SD) 9.21; L-carni-
tine) versus 23.67 (SD 11.24; placebo) (P value= 0.61).
Acetyl-L-carnitine versus amantadine
In another study of 36 participants, acetyl-L-carnitine was com-
pared with amantadine in patients with multiple sclerosis (
Tomassini 2004). Improvement assessed with the FSS was supe-
rior with L-carnitine compared with amantadine. In addition, L-
carnitine was better tolerated than amantadine. However, differ-
ences in the absolute changes in the FSS did not reach statistical
significance and the number of responders was similar for both
drugs. There was no significant change for the secondary outcome
of clinical scale scores (Fatigue Impact Scale, Beck Depression In-
ventory and Social Experience Checklist). The fatigue domain of
the Kidney Disease Questionnaire (KDQ) also significantly im-
proved after 12 weeks and 24 weeks of carnitine therapy compared
with placebo in 56 patients with end-stage renal disease, but did
not significantly affect the total score (Brass 2001).
Acetylsalicylic acid versus placebo
Wingerchuk 2005 was able to show significantly better relief of fa-
tiguewith 1300mg/day of acetylsalicylic acid compared toplacebo
in 26 patients with multiple sclerosis. Wingerchuk et al used the
Modified Fatigue Impact Scale (MFIS) and Kurtzke Expanded
Disability Status Scale (KEDSS) as instruments. In another study
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of 52 patients with multiple sclerosis (Shaygannejad 2012), 500
mg/day showed a significant decrease in FSS scores. We did not
perform meta-analysis due to the different doses and assessment
instruments.
Alfacalcidol versus placebo
A recent study using alfacalcidol 1 µg/day compared with placebo
was conducted to treat fatigue in 158 multiple sclerosis patients.
The Fatigue Impact Scale (FIS) total score decreased significantly.
’RAYS’ quality of life assessments also improved significantly in
the psychological and social subscale (Barak 2014).
Amantadine versus placebo
Amantadine was used in seven studies of 370 participants with
multiple sclerosis with heterogenous outcomes, showing a ten-
dency towards improved outcomeswith amantadine with different
fatigue instruments and scales (Ashtari 2009; Canadian MSRG
1987; Krupp 1995;Murray 1985; Rosenberg 1988; Shaygannejad
2012; Tomassini 2004). Amantadine was significantly better than
placebo on the MS-Fatigue scale. One study of 25 participants
used amantadine post-polio using the Fatigue Severity Scale (FSS)
without proving efficacy (Stein 1995).
Amantadine versus other drugs
Krupp1995 tested amantadine against pemoline (93participants).
No difference between amantadine and pemoline was seen on the
FSS. On the other hand, Tomassini 2004 performed a compari-
son of amantadine against acetyl-L-carnitine (ALCAR). ALCAR
showed superior effect to amantadine. Shaygannejad 2012 tested
amantadine against acetylsalicylic acid. Both groups showed a sig-
nificant decrease in the FSS.
Armodafinil versus placebo
Armodafinil was tested in 70 patients with HIV to evaluate its
efficacy and safety for fatigue and depressive symptoms. In inten-
tion-to-treat analyses, the fatigue response rate to armodafinil was
75% and to placebo 26% (Rabkin 2011). Armodafinil appeared
to be effective in alleviating fatigue and was well tolerated. For
the secondary endpoint depression, measured with the Hamilton
Depression Rating Scale (HDRS) and Beck Depression Inventory
(BDI), a significant effect was not shown. However, further mul-
ticentre studies with larger samples are needed.
Dexamethasone versus placebo
Dexamethasone 4 mg was compared with placebo in a recent
study to treat fatigue in 84 participants with advanced cancer. The
study showed that dexamethasone was significantly superior to
placebo (Yennurajalingam 2013). However, there was no signif-
icant difference in the improvement of individual symptoms on
the Edmonton Symptom Assessment Scale (ESAS), psychological
distress, anxiety scores on the Hospital Anxiety and Depression
Scale (HADS) or HADS depression scores in the dexamethasone
group compared with placebo. Further dexamethasone studies are
needed.
Dextroamphetamine versus placebo
Dextroamphetaminewas comparedwith placebo to treat fatigue in
a study of 39 cancer patients (Auret 2009) and in 22 patients with
HIV (Wagner 2000).Neither study showed significant effects. The
secondary outcome quality of life, which was measured using the
McGill Quality of Life Questionnaire (MQOL), also showed no
significant effect (Auret 2009).
Donepezil versus placebo
In a large study with 142 participants with cancer, donepezil sig-
nificantly relieved fatigue intensity in both the intervention and
control arms, with no significant difference as measured by the
FACIT-F scale. Edmonton Symptom Assessment Scale (ESAS)
and sleep pattern assessment were also used as supplemental scales.
Neither showed significant effects. Thus, donepezil did not appear
to be superior to placebo (Bruera 2007).
Fluoxetine versus placebo
Another study of 129 patients with multiple sclerosis showed that
20 mg of fluoxetine over 12 weeks appeared to be superior to
placebo as measured by the change in Functional Assessment of
Cancer Therapy -General (FACT-G) scores. The fluoxetine group
also showed significant improvement on the depression scale (P
value = 0 .0005) compared with placebo, which was measured
using theBrief ZungSelf-RatingDepressionScale (BZSDS) (Fisch
2003).
Fluoxetine versus testosterone
Fluoxetine was inferior to testosterone in 90 patients with HIV
and fatigue, while the difference in the effect on depression, as
measured with the HDRS, was non-significant (P value = 0.38)
(Rabkin 2004).
Medroxyprogesterone versus placebo
Medroxyprogesterone was tested in only one study of 134 partic-
ipants using the European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC-QLQ-
C30) (Simons 1996). The use of 500 mg twice a day over 12 weeks
showed no significant effect.
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Megestrol acetate versus placebo
Megestrol acetate was tested in 255 patients with cancer. The ad-
ministration of 320 mg/day for 12 weeks was performed to inves-
tigate the effect of megestrol acetate on quality of life, appetite,
weight and survival. However, megestrol acetate does not appear
to improve global quality of life asmeasured by the EORTCQLQ-
C30 (Westman 1999).
Methylphenidate versus placebo
Five studies testedmethylphenidate in 318 cancer patients (Bruera
2006; Butler 2007; Escalante 2014; Moraska 2010; Roth 2010).
Meta-analysis was possible only for two studies (Bruera 2006;
Butler 2007), which used FACIT-F as the assessment tool in
fatigue, comparing methylphenidate with placebo. The studies
showed a slightly superior effect of methylphenidate compared to
placebo (standardised mean difference (SMD) 0.49, 95% confi-
dence interval (CI) 0.15 to 0.83; Analysis 1.1; Figure 4). Moraska
2010 used theBrief Fatigue Inventory (BFI) instrument, and could
not show significant effects of methylphenidate (18 mg to 54 mg)
compared with placebo. Escalante 2014 used a stable dose (18mg)
for twoweeks. They reported thatmethylphenidate improved can-
cer-related fatigue according to the BFI scores. The smallest dose
was used by Roth 2010 (5 mg to 30 mg). In this study, clinically
significant improvement was seen on the BFI.
Figure 4. Forest plot of comparison: 1 Methylphenidate vs Placebo in cancer, outcome: 1.1 FACIT-F score
change.
The other study of 30 participants using methylphenidate con-
cerned the treatment of fatigue in multi-type advanced dis-
ease (hospice) patients (Kerr 2012). The study showed that
methylphenidate was superior to placebo, although the improve-
ment of the fatigue score was dose-dependent, as measured by
Piper Fatigue Scale, Visual Analogue Scale for Fatigue and ESAS.
However, secondary outcomes of depressive symptoms, measured
with the revised BeckDepression Inventory-II (BDI-II), the ESAS
depression score and the Center for Epidemiologic Studies De-
pression Scale (CESD), showed no statistically significant differ-
ences.
Methylphenidate was also investigated in 209 HIV patients and
comparedwith pemoline and placebo (Breitbart 2001). This study
demonstrated a significantly higher number of responders using
methylphenidate compared with placebo.
Methylprednisolone versus placebo
Methylprednisolone (125 mg/day for eight weeks) was used with
significant effect in only one study of 403 participants with cancer-
related fatigue (Della Cuna 1989).
Mistletoe extract PS76A2 versus placebo
Mistletoe extract was tested in 337 patients with breast cancer
(Semiglazov 2006). It showed a significant positive effect using the
FACT-G.
Modafinil versus placebo
Modafinil has been explored for the treatment of fatigue in two
studies of 704 patients with cancer (Jean-Pierre 2010; Spathis
2014). The Jean-Pierre 2010 study showed a significant interaction
between treatment condition (modafinil 200mg/day) andbaseline
fatigue, where patients with severe baseline fatigue benefited from
modafinil and patients with mild or moderate fatigue did not. A
recent study demonstrated that both modafinil (100 to 200 mg/
day) and placebo led to a clinically significant improvement in
FACIT-F scores (Spathis 2014). However, there was no significant
difference between placebo and modafinil.
Though modafinil has been tested in several studies in multi-
ple sclerosis, we found only two controlled trials (Lange 2009;
Stankoff 2005). The Stankoff 2005 study included a larger num-
ber of participants (n = 115), but failed to demonstrate the su-
periority of modafinil versus placebo. Lange 2009 included only
21 participants and stated that they used a subpopulation of a
larger trial. Thus, although there was a clear beneficial effect of
modafinil, this result must be interpreted with caution due to the
small participant numbers. Meta-analysis of these two studies also
failed to demonstrate a significant effect, with a SMD of -0.14
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(95% CI -0.48 to 0.21; Analysis 2.1; Figure 5).
Figure 5. Forest plot of comparison: 4 Modafinil in multiple sclerosis, outcome: 4.1 Modafinil.
Modafinil was also tested for the treatment of fatigue in 33 partic-
ipants with post-polio syndrome (Vasconcelos 2007). However, in
this studymodafinil failed to demonstrate superiority over placebo.
There was also a trial usingmodafinil for fatigue in 105HIV/AIDS
patients (Rabkin 2010). In the intention-to-treat analyses, the fa-
tigue response rate to modafinil was 73% and to placebo 28%;
the attrition rate was 9%. Secondary endpoints (depression), in-
cluding the Hamilton Depression Rating Scale (HDRS) and Beck
Depression Inventory (BDI), did not show a significant effect.
Paroxetine versus placebo
Paroxetine was tested in a study of 479 patients with cancer
(Morrow 2003), and a study of 15 patients with end-stage chronic
obstructive pulmonary disease (COPD; Lacasse 2004). Neither
study showed significant effects. However, the Center for Epi-
demiological Studies Depression (CESD) score, controlling base-
line depression scores, confirmed that the dose of paroxetine pro-
vided was more effective than placebo in reducing depression (P
value = 0 .001).
Pemoline versus placebo
Pemoline was used for the treatment of fatigue in 41 participants
with multiple sclerosis. However, in this study pemoline failed to
demonstrate superiority over placebo (Weinshenker 1992).
Pemoline versus other drugs
Pemoline was tested in 93 patients with multiple sclerosis and se-
vere fatigue (Krupp 1995). The drug did not appear to be superior
to placebo. One study with HIV patients compared pemoline to
methylphenidate and to a placebo (Breitbart 2001). The Breitbart
2001 study demonstrated a significantly higher number of respon-
ders with pemoline and methylphenidate compared with placebo.
Meta-analysis was possible for two studies in multiple sclero-
sis patients as they all included a control group with placebo
and reported continuous outcome indicators (Krupp 1995;
Weinshenker 1992). There was no superior effect of pemoline
(SMD -0.02; 95% CI -0.12 to 0.08; Figure 6).
Figure 6. Forest plot of comparison: 3 Pemoline in multiple sclerosis, outcome: 3.1 Fatigue score change.
However, the US Food and Drug Administration (FDA) has de-
cided to withdraw pemoline products (marketed as Cylert) due to
the risk of liver toxicity, which outweighs the benefits of the drug.
All manufacturers have agreed to stop the sale and marketing of
pemoline (FDA 2005).
Testosterone versus placebo
Testosterone cypionate was investigated in 208 patients with HIV
in three studies by the same workgroup (Knapp 2008; Rabkin
2000; Rabkin 2004). The older study included HIV patients with
symptoms of hypogonadism and found that testosterone relieved
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these symptoms in patients with fatigue at baseline (Rabkin 2000).
However, fatigue intensity on the CFS merely showed a positive
trend, but no significant difference from placebo. The newer study
did not show any significant benefit of testosterone compared to
fluoxetine or placebo (Rabkin 2004). Only Knapp 2008 showed
superiority of testosterone over placebo.
D I S C U S S I O N
This review updates the original review ’Pharmacological treat-
ments for fatigue associated with palliative care’ (Peuckmann-Post
2011) and also incorporates ’Drug therapy for the management
of cancer-related fatigue’ (Minton 2010). Peuckmann-Post 2011
and Minton 2010 included 22 and 31 studies, respectively. This
updated review includes seven studies from Minton 2010 and 22
studies from Peuckmann-Post 2011.
Summary of main results
This systematic review update identified 45 studies for inclusion,
with a wide range of underlying diseases and drug interventions.
Treatment results pointed to weak and inconclusive evidence for
the efficacy of amantadine, pemoline and modafinil in multiple
sclerosis and for carnitine and donepezil in cancer-related fatigue.
Methylphenidate and pemoline seem to be effective in patients
with HIV, but this is based only on one study per intervention,
with only a moderate number of participants in each study. Meta-
analysis shows an estimated superior effect for methylphenidate
in cancer-related fatigue, but not for pemoline and modafinil in
multiple sclerosis. Therapeutic effects could not be described for
dexamphetamine, paroxetine or testosterone.
Acetylsalicylic acid demonstrated surprising efficacy in patients
with multiple sclerosis (Shaygannejad 2012; Wingerchuk 2005).
However, this result was not supported by other studies. For clini-
cal recommendation, further research confirming this positive ef-
fect is needed.
Some studies used other drugs, for example mistletoe extract,
megestrol acetate and medroxyprogesterone acetate (Semiglazov
2006; Simons 1996; Westman 1999), but these studies lacked
strong evidence and the clinical use of these drugs is rather rare.
Further studies need to demonstrate their clinical efficacy.
The available evidence from randomised controlled trials (RCTs)
is scarce, even though there is a surplus of case reports and uncon-
trolled trials. It has to be kept in mind that many of the included
studies involved only a small number of participants (Lacasse
2004; Rosenberg 1988), and did not follow a consistent research
methodology. In some cases the investigated population was very
heterogenous and any outcome may have been associated with
depression (Breitbart 2001; Wagner 2000), making it difficult to
distinguish from primary fatigue. Fatigue often occurs in clusters,
and fatigue and emotional distress are often concurrent factors.
The National Comprehensive Cancer Network (NCCN) guide-
lines discuss studies, some of which show fatigue as an indepen-
dent factor of depression, while others report moderate correla-
tion. The 2014 NCCN guidelines recommended that the psy-
chostimulant methylphenidate may be considered with caution
for the pharmacological treatment of fatigue in selected patients.
However, corticosteroids are recommended for short-term but not
long-term therapy, due to their toxicity (NCCN 2014).
Treatment of secondary fatigue should be initiated with the treat-
ment of the underlying cause. Some causes of secondary fatigue,
such as anaemia, depression, infection, dehydration,malnutrition,
hypercalcaemia, hypomagnesaemia, other metabolic disorders or
the side effects of treatment with opioids and other sedative drugs,
should also be treated, though little evidence from randomised
trials is available on the efficacy of these treatments (EAPC 2008).
This review only included studies specifically focusing on palliative
care in patients with advanced disease with the aim of relieving
fatigue. Studies investigating curative treatment (e.g. treatment of
early breast cancer) and fatigue directly related to treatment were
not included in this review.
In addition, the results of the literature search indicate that recent
research interest focuses on modafinil (eight studies) and its use in
fatigue management for palliative care patients. This may be an
interesting future perspective.
Potential biases in the review process
None of the authors of this review were involved in any of the
excluded or included studies. In addition, none of the authors has
any conflict of interest. Our search strategy was as comprehensive
as possible. All studies were independently assessed for inclusion
by two review authors so we are confident that we have included
all relevant studies and attempted to reduce bias in the review
process.
Due to difficulties in conducting these types of trials for any of
these drugs, trials may not have been published at all. Therefore,
there is the potential for publication bias in this review. However,
by contacting experts in this field we have attempted to reduce
this bias as much as possible.
Agreements and disagreements with other
studies or reviews
There have been two previous Cochrane Reviews (Minton 2010;
Peuckmann-Post 2011), which are merged in this systematic re-
view using a new search strategy to increase its coverage. Minton
2010 concluded in their last published version that there is in-
creasing evidence that psychostimulant trials improve cancer-re-
lated fatigue at a clinically meaningful level. This review described
the need for a large-scale RCT of methylphenidate to confirm
the preliminary results from their review. They recommended
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haemopoietic growth factors for the treatment of cancer-related
fatigue. However, with new safety data indicating increased ad-
verse outcomes, these drugs can no longer be recommended in the
treatment of cancer-related fatigue (Bennet 2008; Bohlius 2009;
EAPC 2008; Glaspy 2009; Tonelli 2009). Peuckmann-Post 2011
concluded that, based on limited evidence, they could not recom-
mend a specific drug for the treatment of fatigue in palliative care
patients. The review pointed out that until 2009, corticosteroids
had not been the focus of research on fatigue treatment, although
these drugs were frequently used in clinical practice. This review
also stated that fatigue research seems to focus onmodafinil, which
may be beneficial, although there is no evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review update found no evidence to support the use of a
specific drug to treat fatigue in palliative care patients. Amanta-
dine seems to be promising in patients with multiple sclerosis and
fatigue, while methylphenidate is advantageous in patients with
cancer-related fatigue. However, since the number of studies ex-
amining the effect of these drugs on fatigue, as well as the par-
ticipant numbers, were relatively low, the evidence remains weak.
Whether amantadine also relieves fatigue in cancer patients and
whether methylphenidate relieves fatigue in multiple sclerosis pa-
tients has not been shown but should be investigated. Further
studies are needed in patients with advanced disease and fatigue
to show whether dexamethasone, methylprednisolone, donepezil,
carnitine or modafinil may be beneficial, since the available evi-
dence currently does not support these interventions.
Overall, most adverse effects of the investigated drugs seemed to
be fairly moderate. Patients withHIV/AIDS and fatigue should be
offered treatment with methylphenidate or pemoline. Similarly,
other drugs may be tested, if the above-mentioned drugs are not
available.
Clinical practice includes corticosteroids as a short-term thera-
peutic option for relief of fatigue in palliative care (Radbruch
2008; Yennurajalingam 2013). However, only one randomised
controlled trial (RCT) from our literature search matched the in-
clusion criteria (Yennurajalingam 2013). There are still not enough
studies to show the therapeutic benefits of corticosteroids for this
indication.
Implications for research
Patient group
Trials with a higher participant numbers may be able to detect
small differences between groups. Palliative care studies in patients
with advanced diseases, with the aim of relieving primary or sec-
ondary fatigue, should remain a focus of research. Further trials in-
vestigating subpopulations with different diseases in the end stage
may be helpful. Stratification according to sociodemographic vari-
ables should be performed since, for example, younger age and
male sex have been shown to predict worse fatigue (Auret 2009;
Butler 2007).
Interventions
Amantadine, methylphenidate, carnitine, acetylsalicylic acid, dex-
amethasone, alfacalcidol, armodafinil and modafinil have been
used in a few studies in this review with positive results. These
drugs should be investigated in more detail to confirm their ef-
ficacy and should be examined for potentially similar efficacy in
populations with different diseases and related fatigue. For in-
stance, amantadine has been studied exclusively in multiple sclero-
sis patients and in post-polio studies. Therefore, it may be relevant
to examine the effect of amantadine in other populations, such
as cancer patients. Also, investigation of corticosteroids in RCTs
would be highly relevant.
Comparisons
Future trials should compare one anti-fatigue drug to another anti-
fatigue drug, combined with placebo-controlled comparisons.
Outcomes
There is no consensus on threshold values for relief of fatigue or on
criteria for the responder. Patient-reported fatigue and variance in
the outcome instruments could be used to measure the improve-
ment of fatigue. Outcomes should also clearly define both the re-
sponse and adverse effects from the treatment. It would be helpful
to agree on the use of particular measurement instruments in order
to perform better comparisons and analysis (Minton 2009).
Trial design
Further research is needed to identify effective and safe treatment
for fatigue in palliative care. Multi-centre RCTs are recommended
to assess the value of pharmacological treatments for fatigue. Ad-
ditional data are required to confirm the results of this review and
to provide a more significant estimate of efficacy.
Overall, this review demonstrates a lack of evidence rather than a
lack of efficacy of the interventions.With regard to future research,
studies with larger participant numbers are needed. However, the
difficulties of low recruitment and high attrition rates have been
described repeatedly in research in palliative care, as patients with
advanced and life-threatening diseases are involved. It would also
be helpful to limit the diversity of scales and scores used. Since no
standardised recommendations for assessment of fatigue yet exist,
it is difficult to determine whether the outcome measures were
appropriate.Minton and Stone have suggested using the European
Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (EORTC-QLQ-C30) fatigue subscale or the
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Functional Assessment of Cancer Therapy fatigue scale (Minton
2009).
Interestingly, there were no more than two studies with a focus on
corticosteroids and fatigue as the primary outcome (Della Cuna
1989; Yennurajalingam 2013), although corticosteroids have been
recommended (EAPC 2008) and are frequently used for this in-
dication by clinicians since clinical experience shows a beneficial
effect on many of the symptoms experienced by palliative care
patients. The impact of corticosteroids should be investigated in
future studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ashtari 2009
Methods Placebo-controlled RCT
Participants N = 42 patients with multiple sclerosis who were divided randomly into 2 groups
Interventions Amantadine 200 mg/day
Duration: 2 months
Outcomes FSS scores at baseline and 2 months later were compared in the 2 groups
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identical preprinted medication code labels
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals < 10%
Size of study High risk < 50 participants per treatment arm
Auret 2009
Methods Placebo-controlled, DB, RCT
Participants N = 70 pts with advanced cancer and cancer considered, 50 included
Interventions Dexamphetamine 10 mg/twice a day or placebo
Duration: 8 days
ITT basis
Outcomes BFI, McGill Quality of Life Questionnaire, ECOG; side effects monitored. Pts were
included if they reported fatigue as at least 4 of 10 on a 0 to 10 NRS. Reduction by 2
points on a 10-point scale (BFI) was considered aminimum important clinical difference
Notes -
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Auret 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The active drug and the placebo were pre-packed in
identical generic capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Barak 2014
Methods Double-blind, randomised, placebo-controlled trial
Participants N = 158 pts with multiple sclerosis
(mean age 41.1 + 9.2 years)
Interventions Patients were randomly assigned to receive alfacalcidol (1 µg) or placebo once daily for
6 months
Outcomes FIS and QOL
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Baseline observation carried forward
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Barak 2014 (Continued)
Size of study Unclear risk Participants 50 to 199 per treatment arm
Brass 2001
Methods Placebo-controlled, DB, RCT
Participants N = 60 pts with end-stage renal disease (ESRD)
Interventions Patients were randomised and divided into 2 groups 1:1; placebo and treatment
Study A: treatment with L-carnitine 20 mg/kg IV for 24 weeks
Study B: treatment with L-carnitine dose-ranging 10 to 20 to 40 mg/kg for 24 weeks
Outcomes KDQ
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis;
withdrawals < 10%
Size of study High risk < 50 participants per treatment arm
Breitbart 2001
Methods Placebo-controlled, DB, RCT
Participants HIV pts with fatigue receiving ambulatory care
Interventions Titration up to max. 60 mg methylphenidate or 150 mg pemoline, or 8 capsules placebo
daily
Duration 6 weeks
Outcomes PFS, VAS-F; side effects monitored
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Breitbart 2001 (Continued)
Notes The authors concluded that pts responded favourably to both treatments. However,
while the PFS total score showed a significant difference, the VAS total fatigue scale (in
which the energy score was significant only) did not. Therefore, the authors’ conclusion
seems to be too positive
A confounding factor may have been improvement in fatigue due to an antidepressant
effect, according to the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used block randomisation
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All medications were prepared in identical capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Bruera 2006
Methods Placebo-controlled, patient-controlled, DB, RCT
Participants N = 112 cancer pts with a fatigue score of at least 4 on a scale of 0 to 10 were included
Interventions Pts were randomised to methylphenidate 5 mg PO or placebo every 2 hours prn (max 4
times/day) for 1 week, followed by a 4-week open-label trial of methylphenidate
Outcomes FACIT-F, ESAS, daily diary. The authors proposed to detect a decrease in fatigue in the
methylphenidate group over and above the placebo group, of half the SD, or a score
of approximately 7 on the FACIT-F scale. They therefore adjusted the sample size to
declare this difference statistically significant, assuming a one-sided significance level of
0.05 and 80% power
Notes The authors stated that a longer study duration of more than 1 week was justified
Risk of bias
Bias Authors’ judgement Support for judgement
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Bruera 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Restricted random assignment with ran-
dom balance points from 1 to 5 blocks
Allocation concealment (selection bias) Low risk A list of random assignments was prepared
and the next eligible patient was entered on
the next available assignment line
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’
analysis; withdrawals < 10%
Size of study Unclear risk Participants 50 to 199 per treatment arm
Bruera 2007
Methods PC, DB, RCT
Participants Pts with fatigue score of at least 4 on a scale of 0 to 10 were included; 112 of 142 pts
with cancer fatigue were assigned to treatment (71 each)
Interventions Patients were randomised to donepezil 5 mg PO or placebo every morning for 1 week.
Second week: open-label
Outcomes FACIT-F, ESAS
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Restricted random assignmentwith randombalance points from
1 to 5 blocks
Allocation concealment (selection bias) Low risk A list of random assignments was prepared and the next eligible
patient was entered on the next available assignment line
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
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Bruera 2007 (Continued)
Size of study Unclear risk Participants 50 to 199 per treatment arm
Butler 2007
Methods PC, DB, RCT, phase III trial
Participants N = 68 pts with primary or metastatic brain tumour scheduled to receive radiotherapy;
34 pts included in each group
Interventions D-threo-methylphenidate HCl 5 mg/twice a day, titrated to max. 15 mg/twice a day,
duration 12 weeks
Outcomes Cognitive function, FACIT-F, Center for Epidemiologic Studies scale, MMSE, KPS
Assessed at baseline, end of RT and 4, 8 and 12 weeks after brain RT
Notes This study examines prophylactic treatment (before and after RT). The population was
quite heterogenous, since approximately half of the pts had metastatic disease and 75%
received radiotherapy without chemotherapy. The age range was 28 to 83 years (median
52 for verum and 60 years for placebo group)
There was a 71% drop-out from baseline (n = 33 methylphenidate group, n = 29 placebo
group) until weeks 5 to 12 (n = 9 each group). Further, the post-treatment effect of
radiotherapy during a 12-week coursemay vary concerning fatigue and pain, for example,
which in part may be caused or relieved by the treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants received a bottle of pills containing either
the study drug or a matched placebo
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
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Canadian MSRG 1987
Methods PC, DB, RCT, cross-over; multicentre trial (11 MS centres)
Participants N = 115 of 159 were randomised to treatment
Eligible participants had at least a 6-month history of “definite multiple sclerosis” and a
3-month history of chronic, persistent, moderate to severe daily fatigue
Interventions Amantadine 100 mg/twice a day or placebo
10 weeks duration
2 x 3-week treatment periods
Each treatment period was preceded by a single-blind, 2-week placebo period
Outcomes KEDSS; BDI; VAS-F
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’
analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Cohen 1989
Methods DB, RCT, cross-over, single centre
Participants N = 29 eligible participants had “satisfied criteria for a definite/probable diagnosis of
multiple sclerosis” at least 6 months before diagnosed; all had daily symptomatic fatigue
for at least 3 months
Interventions Random assignment to 100 mg amantadine Hcl twice a day or placebo for 4 weeks,
followedby a 2-weekwash-out, then cross-over to an alternate treatment (verum/placebo)
for another 4-week-period
Outcomes Kurtzke rating; mBDI, “Stroop Interference Test” (attentional measure of freedom from
distracting information). “Overall fatigue” was averaged across mean diary ratings for 7
indices of fatigue on a 5-point scare; 1 = poor; 5 = excellent)
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Cohen 1989 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analy-
sis
Size of study High risk < 50 participants per treatment arm
Cruciani 2009
Methods PC, DB, RCT
Participants N = 149 eligible pts with carnitine deficiency, cancer and fatigue (n = 27 were excluded
due to screen failure)
Interventions L-carnitine (initial dose 0.5 g/day for 2 days, followed by 1 g/day for 2 days, then 2 g/day
for 10 days or placebo), followed by an open-label phase, during which all pts received
L-carnitine for 2 weeks
Outcomes FACT-An, LASA, MMSE, KPS
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer program
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The liquid carnitine and placebo were prepared by a research
pharmacist and were identical in appearance and taste
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Cruciani 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Cruciani 2012
Methods PC, DB, RCT phase III trial
Participants 376 pts with cancer
Interventions Pts were randomly assigned to either 2 g/day of L-carnitine oral supplementation or
matching placebo for 4 weeks
Outcomes BFI, FACIT-F
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation system
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Drug and placebo matched in appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Della Cuna 1989
Methods PC, DB, RCT
Participants 403 pts with cancer
Average age 62.7
Interventions Methylprednisolone 125 mg/day IV 8 weeks
Matching placebo
Outcomes NOSIE, LASA, the Physicians’ Global
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Della Cuna 1989 (Continued)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Escalante 2014
Methods Placebo-controlled, DB, RCT - cross-over
Participants N = 42 pts were enrolled and were diagnosed with lymphoma, myeloma or breast, gas-
trointestinal or lung cancers, and either undergoing chemotherapy or hormonal treat-
ment or completed treatment in the previous 12 months
Interventions The study duration was 4 weeks. Patients were randomised into 1 of 2 arms:
Methylphenidate (18 mg/day) for 2 weeks followed by placebo for 2 weeks (arm A) or
placebo for 2 weeks followed by methylphenidate (18 mg/day) for 2 weeks (arm B)
Outcomes BFI at the end of each 2-week period
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
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Escalante 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’
analysis
Size of study High risk < 50 participants per treatment arm
Fisch 2003
Methods PC, DB, RCT
Participants 163 pts with cancer
Interventions Fluoxetine 20 mg/day 12 weeks
Outcomes FACT-G, BZSDS
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Preprinted randomisation table
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Jean-Pierre 2010
Methods Placebo-controlled, DB, RCT, phase III
Participants 877 cancer patients enrolled in the study
N = 431 (modafinil) and n = 436 (placebo)
Majority of sample were Caucasian and reported diverse marital status and educational
level. 67% of the participants were females at baseline
Interventions 100 mg of modafinil or placebo on day 10 of the chemotherapy cycle, then increase to
the full dose of 200 mg of modafinil or placebo after 3 days and continue on this regimen
until day 7 of study cycle 4
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Jean-Pierre 2010 (Continued)
Outcomes BFI, ESS, POMS-DD
Fatigue and depression were assessed during cycles 2 to 4 using psychometrically valid
measures
Group differences (treatment versus control) in the worst level of fatigue during the
previous week at cycle 4 were examined using an analysis of covariance (ANCOVA)
adjusting for baseline fatigue (cycle 2)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number generator program
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’
analysis
Size of study Low risk > 200 participants per treatment arm
Kerr 2012
Methods Placebo-controlled, DB, RCT
Participants N = 30 pts with advanced disease in hospice hospital
2 weeks duration
Interventions Pts were randomly assigned to receive either 5 mg of methylphenidate or placebo at 8 am
and 1 pm. Doses of methylphenidate were titrated every 3 days according to response
and adverse effects. Home care patients were monitored daily by telephone and visited
by a research nurse on study days 0 (baseline), 3, 7 and 14
Outcomes PFS, VAS-F, ESAS, BDI-II, ESAS depression score, CESD
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Kerr 2012 (Continued)
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Knapp 2008
Methods PC, DB, RCT
Participants 61 patients with HIV
Interventions 300 mg IM of testosterone enanthate or placebo for 16 weeks
Outcomes Body composition, muscle strength, physical function and MOS-30
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
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Krupp 1995
Methods PC, DB, RCT
Participants N = 119 pts with multiple sclerosis and severe fatigue were eligible (FSS score at least
4 of 7; 9 items, each with potential score of 1 to 7; scoring is done by calculating the
average response)
Interventions Pts were randomised to treatment with pemoline (18.75 mg/day for 1 week, 37.5 mg/
day for week 2, and 56.25 mg weeks 3 to 6) or placebo or amantadine (amantadine 100
mg twice a day) for 6 weeks
Outcomes FSS, MS SFS, subjective response (verbal rating)
Notes Authors conclude that “amantadine was significantly better than placebo in treating fa-
tigue in MS patients”, however, this applies only to ratings on the MS Specific Fatigue
Scale, not on the FSS. Interestingly, the authors chose a FSS cut-off score as an inclusion
criterion, which highlights this scale as a key instrument. Thus, a clear effect of aman-
tadine on fatigue seems questionable
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Drugs including the matching placebo were delivered by the
pharmaceutical industry
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Lacasse 2004
Methods PC, DB, RCT
Participants N = 23 of 342 pts with end-stage COPD were found eligible (n = 82 refusals)
12-week duration
Interventions Paroxetine was started at a dose of 5 mg/day, with weekly 5 mg increments up to a
maximum of 20 mg/day “or the highest dose not associated with any side effect”
Outcomes SF-36, “chronic respiratory questionnaire (CRQ)”: 1 of 4 domains was fatigue (each
domain includes 4 to 7 items and each item is scored on a 7-point-scale.); geriatric
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Lacasse 2004 (Continued)
depression scale
Notes 342 pts were assessed for eligibility; 319 pts were excluded to ineligibility (237 pts) and
refusal (82 pts)
Primary outcome was quality of life
Very low number of participants. Power analysis was conducted: 80% was reached at
sample size of 9 to detect large treatment effects (type I error 0.05). This number has
not been reached
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Low risk Randomnumbers table was used to allocate participants to treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Lange 2009
Methods PC, DB, RCT
Participants N = 21 pts with multiple sclerosis and fatigue
8-week duration
Interventions Placebo or modafinil was started at a dose of 100 mg/day for the first week and 200 mg/
day for the subsequent 7 weeks
Outcomes FSS, FSS sum score was used (potential scores 4 to63), alertness test, NHPT, TMS
Notes The authors state that “the TMS subgroup consisted of 21 consecutive multiple sclerosis
pts from a larger, randomised, double-blind trial”
Risk of bias
Bias Authors’ judgement Support for judgement
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Lange 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Lou 2009
Methods PC, DB, RCT pilot study
Participants 19 pts with Parkinson’s disease
Duration 8 weeks
Interventions Participants took their regular medications and were randomly assigned to the treatment
group (9 participants, modafinil 100 mg capsule twice a day PO) or placebo group (10
participants) twice a day for 8 weeks
Outcomes MFI, ESS, CESD
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Placebo group and treatment had the same appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; with-
drawals < 10%
Size of study High risk < 50 participants per treatment arm
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Moraska 2010
Methods PC, DB, RCT phase III study
Participants 148 pts with cancer were enrolled for this study
Interventions Pts were randomly assigned to receive 1 tablet of methylphenidate or placebo on days 1
through 7, 2 tablets on days 8 through 14, and 3 tablets on days 15 through 28. Each
methylphenidate tablet was 18 mg, resulting in the goal dose of 54 mg/day for the final
2 weeks of the study. Tablets were to be taken in the morning
Outcomes BFI, SED, SF-36 Vitality Subscale, LASA, PSQI, SGIC
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Centrally allocated randomisation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Morrow 2003
Methods PC, DB, RCT
Participants N = 549 of 704 cancer patients with fatigue (recruited on days 1 to 3 undergoing
chemotherapy)
Interventions Paroxetine 20 mg/day oral or placebo for 8 weeks
Outcomes FSC, MAF (total score was substituted by score of question no. 1; potential score 1 to
10), MPMM, CESD. Assessments were performed at cycles 3 and 4 of chemotherapy
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Morrow 2003 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers table
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication and placebo were identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Low risk > 200 participants per treatment arm
Murray 1985
Methods PC, DB, CT, cross-over
Participants N = 40 pts with multiple sclerosis and persistent fatigue of at least 3 months’ duration
Interventions Amantadine 100 mg or placebo twice a day
6 weeks “with one week wash-out period between active drug and placebo”
Outcomes KDSS; improvement of fatigue measured by percentage of participants who felt im-
provement
Notes The authors reported that “In only a few instances the same patients were used in more
than one study”. Date of study investigation was 1985 and methods may have been
different
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
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Rabkin 2000
Methods PC, DB, RCT
Participants N = 74 HIV-positive men with hypogonadal symptoms (diminished libido, depressed
mood, low energy, depleted muscle mass) and symptomatic HIV illness
Interventions Testosterone cypionate IM injections (initial dose 200 mg, increased to 400 mg) bi-
weekly for 6 weeks, followed by 12-week open-label maintenance
Outcomes CGI scale ratings for libido, mood, energy and erectile function; CFS (7-item scale
measured by response options from 1 = never to 5 = always)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of numbers
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Matching coded vials containing medication or placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; withdrawals
< 10%
Size of study High risk < 50 participants per treatment arm
Rabkin 2004
Methods PC, DB, RCT
Participants HIV-positive men
N = 123 men were found eligible
Interventions Testosterone cypionate IM injections (initial dose 200 mg, increased to 400 mg bi-
weekly, or fluoxetine up to 60 mg/day (starting dose not mentioned; final mean dose 34
mg, range 20 mg to 40 mg)
Outcomes CGI scale rating “was expanded to include ratings of energy, as well as mood and a global
rating (CGI), significant improvement was defined as score of 1 or 2 on CGI”; HDRS;
CFS scores (7-item scale measured by response options from 1 = never to 5 = always)
Notes Overall, the authors did not recommend testosterone as first-line treatment for depressive
disorders in HIV-positive men, but suggested further investigation in pts experiencing
fatigue as well as depression
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Rabkin 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of numbers
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Matching coded vials containing medication or placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; withdrawals
< 10%
Size of study High risk < 50 participants per treatment arm
Rabkin 2009
Methods PC, DB, RCT
Participants 32 patients with amyotrophic lateral sclerosis (ALS)
Interventions Modafinil 300 mg/day
Duration 4 weeks
Outcomes CGI improvement scale, FSS, ESS, BDI, RFS and VAS
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Centrally allocated randomisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication and placebo were identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
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Rabkin 2009 (Continued)
Size of study High risk < 50 participants per treatment arm
Rabkin 2010
Methods PC, DB, RCT
Participants 115 pts with HIV/AIDS
Interventions Modafinil with maximum dose 200 mg/day for 8 weeks
Outcomes CGI improvement, FSS, HDRS, BDI. Safety assessment used assays of CD4 cell count
and HIV RNA viral load
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of numbers
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication and placebo were identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Rabkin 2011
Methods PC, DB, RCT
Participants 70 pts with HIV
Interventions Maximum trial dose of armodafinil was 250 mg/day for 4 weeks
Outcomes CGI, FSS, HDRS and BDI. Safety was assessed with assays of CD4 cell count and HIV
RNA viral load and the SAFTEE side effects rating scale
Notes -
Risk of bias
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Rabkin 2011 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of numbers
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication and placebo were identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; withdrawals
< 10%
Size of study High risk < 50 participants per treatment arm
Rosenberg 1988
Methods PC, DB, RCT
Participants N = 10 pts with multiple sclerosis
Interventions Amantadine 200 mg/day or placebo for 1 week, followed by a 1-week wash-out, followed
by a cross-over to another drug for 1 week
Outcomes KEDSS (potential range 0 to 10; 0 = normal neurological examination, 10 = death),
patient preference
Notes Baseline values of KEDSS were not provided; very small participant number. No infor-
mation concerning a power analysis given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
49Pharmacological treatments for fatigue associated with palliative care (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rosenberg 1988 (Continued)
Size of study High risk < 50 participants per treatment arm
Roth 2010
Methods PC, DB, RCT
Participants N = 32 pts ambulatory with prostate cancer
Interventions The patients were randomly allocated to receive either methylphenidate or placebo for a
period of 6 weeks. Methylphenidate was administered in capsules containing 5 mg each,
with a starting dose of 1 capsule in the morning
The dose was increased by 1 capsule (5 mg) on day 3, added as a midday dose, if fatigue
was not substantially reduced, there was no toxicity from the study treatment and if the
patient was willing to increase the dose. Dosage was titrated upwards (or down) every
2 to 3 days to a maximum of 6 capsules daily, divided into morning and midday doses
(equivalent to a total maximum daily dose of 30 mg of methylphenidate)
Outcomes BFI
Notes The authors suggest the need to monitor pulse and blood pressure during the treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication and placebo were identically appearing capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Semiglazov 2006
Methods PC, DB, RCT
Participants Pts with breast cancer N = 352
Average age 46.2
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Semiglazov 2006 (Continued)
Interventions Standardised mistletoe (PS76A) extract for 6 cycles of chemotherapy; matched placebo
up to 18 weeks
Outcomes FACT-G
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Low risk Centrally allocated randomisation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Medication and placebo were identical in terms of appearance,
colour and packaging
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Shaygannejad 2012
Methods PC, DB, RCT, cross-over
Participants N = 52 pts with multiple sclerosis
Age range 21 to 53 years old
Interventions The first group received amantadine (100 mg twice a day) for a total of 4 weeks. The
second group received 500 mg/day acetylsalicylic acid (ASA) for 4 weeks. After a 2-week
wash-out period, they crossed over to the alternative treatment for 4 weeks
Outcomes FSS
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
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Shaygannejad 2012 (Continued)
Allocation concealment (selection bias) Low risk Group assignments were concealed in an opaque, sealed
envelope
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; with-
drawals < 10%
Size of study High risk < 50 participants per treatment arm
Simons 1996
Methods PC, DB, RCT
Participants N = 206
Male 153, female 53
Average age 64
Interventions Medroxyprogesterone acetate (MPA) 500 mg twice a day for 12 weeks
Outcomes EORTC-QLQ-C30 fatigue subscale
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation in permutation blocks of 4
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
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Spathis 2014
Methods PC, DB, RCT
Participants N = 208 pts with non-small cell lung cancer (NSCLC)
Interventions Modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28) or matched placebo
Outcomes FACIT-F, ESS, HADS, QOL-LAS
Notes Future trials need to have sufficient power to evaluate the effect in those patients with
severe fatigue and could incorporate a placebo wash-in period to minimise the influence
of the placebo effect
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Central telephone system
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The over-encapsulated active drugs and placebo capsules were
matched
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Stankoff 2005
Methods PC, DB, RCT
Participants N = 115 pts with multiple sclerosis and “stable disability”, minimal baseline score on
MFIS of 45
N = 56 modafinil, N = 59 placebo
Interventions Modafinil initial dose 200 mg for 1 week, increased by 100 mg weekly up to 400 mg/
day max., then continued for 2 weeks or placebo
5-week duration
Outcomes MFIS; score range 0 to 84; lower score indicating less fatigue, VAS-F, ESS
Notes -
Risk of bias
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Stankoff 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Blocks of 4 randomisation
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study Unclear risk Participants 50 to 199 per treatment arm
Stein 1995
Methods PC, DB, RCT
Participants N = 25 pts with post-polio syndrome and fatigue were eligible
Interventions Amantadine 100 mg twice a day or placebo for 6 weeks
Outcomes FSS; improvement of fatigue as noted by participants given in percentage
Notes Very small participant numbers. Power analysis was calculated to detect 50% reduction
in fatigue with 80% power and probability of type I error 0.05
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
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Tomassini 2004
Methods DB, RCT, cross-over pilot trial
Participants N = 36 pts with multiple sclerosis and fatigue
Interventions Amantadine 100 mg twice a day or acetyl-L-carnitine (ALCAR) 1 g twice a day for
3 months, followed by a 3-month wash-out period, then followed by a cross-over to
alternative treatment for 3 months
Outcomes FSS, FIS, BDI, SEC; reduction of FSS scores observed in participants given in percentage
Notes Inclusion of relapsing-remitting and secondary progressive multiple sclerosis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Vasconcelos 2007
Methods DB, RCT, cross-over trial
Participants N = 36 pts with post-polio syndrome
N = 18 (modafinil) and n = 18 (placebo)
Interventions Treatment with modafinil or equivalent placebo lasted for 6-week periods, being sepa-
rated by a 14-day wash-out interval. First 3 weeks of treatment, patients received half of
the targeted dose (i.e. 200 mg/day supplied as 2 x 100 mg capsules, 1 at breakfast and
lunch). At the end of the 3rd week patients doubled their intake (i.e. 400 mg/day, 200
mg at breakfast and lunch)
Outcomes FSS, VAS-F, FIS, SF-36 QOL
Notes -
Risk of bias
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Vasconcelos 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Concealed allocations from investigators by securing treat-
ment codes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Active drug and placebo had the same appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Wagner 2000
Methods PC, DB, RCT
Participants N = 23 pts with HIV, depression and debilitating fatigue
Interventions Dextroamphetamine initial dose 2.5 mg twice a day, titrated up to maximum of 40 mg/
day. Mean dose was 26 +/- 12 mg daily, range 10 to 40 mg/day or placebo for 2 weeks,
followed by 24 weeks of open-label trial
Outcomes SCID; HDRS, BFI, BHS, VAS for mood, CFS (possible range 0 to 28), VAS for energy
level
Notes Groups were heterogenous concerning major depression, which was diagnosed in 12 of
the 23 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; withdrawals
< 10%
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Wagner 2000 (Continued)
Size of study High risk < 50 participants per treatment arm
Weinshenker 1992
Methods DB, RCT, cross-over; 2-centre trial
Participants N = 46 pts with multiple sclerosis and fatigue (patients with multiple sclerosis exacerba-
tion during study period were excluded)
Interventions Pemoline titration in 1 week (18.75 mg to 75mg/day), continued for 3 weeks or placebo,
followed by a cross-over to the other treatment
Outcomes VAS-F, KEDSS, mBDI; tolerance of adverse effects and checklist to identify their nature
Notes Interestingly, the authors noted increasing benefit from pemoline over the 2-week study
period and supposed that there may have been a larger treatment effect if the study period
was longer. Of 13 patients who chose to continue taking the drug, 7 were still taking it
after 1 year and reported benefit
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Used ’last observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Westman 1999
Methods DB, RCT, cross-over trial
Participants N = 255 pts with cancer
Male 134, female 121
Average age 70 (not on treatment)
Interventions Megestrol acetate (MA) 320 mg/day
57Pharmacological treatments for fatigue associated with palliative care (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Westman 1999 (Continued)
Outcomes EORTC-QLQ-C30
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation in permutation
blocks of four
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Active drugs and placebo had the same shape, size, appear-
ance, colour and taste
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis; with-
drawals < 10%
Size of study Unclear risk Participants 50 to 199 per treatment arm
Wingerchuk 2005
Methods PC, DB, RCT, cross-over
Participants N = 30 pts with multiple sclerosis and fatigue
Interventions Acetylsalicylic acid (ASA) 1300 mg/day or placebo for 6 weeks, followed by 2-week
wash-out period, followed by cross-over to alternative treatment
Outcomes MFIS (possible score 0 to 84), KEDSS, CESD, Global Fatigue Change self assessment,
VAS
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated random number list
Allocation concealment (selection bias) Low risk Allocation concealment from investigators by securing the
results in the pharmacy
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Wingerchuk 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Active drug and placebo had the same appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
Yennurajalingam 2013
Methods PC, DB, RCT
Participants N = 84 pts with advanced cancer (dexamethasone = 43, placebo = 41)
Interventions Patients were randomly assigned to either dexamethasone 4 mg or placebo orally twice
per day for 14 days
Outcomes ESAS, FACIT-F, HADS, FAACT
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method not described
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Used ’baseline observation carried forward’ analysis
Size of study High risk < 50 participants per treatment arm
BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; BHS = Beck Hopelessness Scale; BZSDS = Brief Zung Self-
Rating Depression Scale; CESD = Center for Epidemiologic Studies Depression; CFS = Chalder Fatigue Scale; CRQ = Chronic
Respiratory Questionnaire; DB = double-blind; ECOG = performance status according to the Eastern Cooperative Oncology Group
Scale; EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; ESAS =
Edmonton Symptom Assessment System; ESS = Epworth Sleepiness Scale; FAACT = Functional Assessment of Cancer Therapy-
Anorexia-Cachexia; FACIT-F = Functional Assessment for Chronic Illness Therapy - Fatigue; FACT-An = Functional Assessment of
Cancer Therapy - Anaemia; FIS = Fatigue Impact Scale; FSC = Fatigue Symptom Checklist; FSS = Fatigue Severity Scale; HADS =
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Hospital Anxiety and Depression Scale; HDRS = Hamilton Depression Rating Scale; IM = intramuscular; ITT = intention-to-treat;
IV = intravenous; KDQ = Kidney Disease Questionnaire; KEDSS = Kurtzke Expanded Disability Status Scale; KPS = Karnofsky
Performance Status; LASA = Linear Analogue Scale Assessments; MAF =Multidimensional Assessment of Fatigue; mBDI =Modified
Beck Depression Inventory; MFI = Multidimensional Fatigue Inventory; MMSE = Mini Mental State Examination; MOS-30 =
Medical Outcomes Study-Short Form 30; MPMM =Monopolar Profile ofMood States; MS =multiple sclerosis; MS SFS =Multiple
Sclerosis Specific Fatigue Scale; NHPT = Nine Hole Peg Test; NOSIE = Nurses’ Observational Scale for Inpatient Evaluation; NRS
= numeric rating scale; PC = placebo-controlled; PFS = Piper Fatigue Scale; PO = per oral; POMS-DD = Depression-Dejection
subscale of the Profile of Mood States; prn = as needed; PSQI = Pittsburgh Sleep Quality Index; pts = participants; QOL = RAYS
quality of life; QOL-LAS = quality of life linear analogue scale; RCT = randomised controlled trial; RFS = Role Function Scale;
RT = radiation therapy; SAFTEE = Systematic Assessment for Treatment Emergent Events; sc = subcutaneous; SCID = depression
according to Structured Clinical Interview for DSM-IV; SD = standard deviation; SE = standard error; SEC = Social Experience
Checklist; SED = Symptom Experience Diary; SF-36 = Short Form-36; SGIC = Subject Global Impression of Change; TMS =
transcranial magnetic Social Experience Checklist; VAS = visual analogue scale; VAS-F = visual analogue scale - fatigue
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agteresch 2000 Open-label study
Bruera 1987 Focus of this study was sedation related to narcotics, not fatigue
Bruera 1998 Focus of study was cancer cachexia
Bruera 2003 Focus of this study was sedation related to narcotics, not fatigue
Capuron 2002 Main focus of this study was not fatigue
Carter 2005 Open-label study, case series
Cerchietti 2004 Not blinded, not a RCT
Cruciani 2004 Open-label study
Cruciani 2006 Phase I/II study
Cueva 2012 Phase II study
Cullum 2004 Open-label study, case series
De Conno 1998 Main focus of this study was depression and appetite
Diel 2004 Part of the study was open-label
Downer 1993 Main focus of this study was cachexia
Dunlop 2007 Focus of this study was depression
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(Continued)
Gehring 2012 Open-label study
Graziano 2002 The drug was intended to treat fatigue, which was induced by a treatment not a disease
Hannestad 2011 The participants were not at an advanced stage of illness or in a palliative situation
Hovey 2014 The drug was intended to treat fatigue, which was induced by a treatment not a disease
Inoue 2003 The drug was intended to treat fatigue, which was induced by a treatment not a disease
Lauretti 2013 Focus of this study was pain
Laval 2008 This article was published only as a protocol; no original results
Lower 2009 The drug was intended to treat fatigue, which was induced by a treatment not a disease
Mar Fan 2008 The drug was intended to treat fatigue, which was induced by a treatment not a disease
McElhiney 2010 Primary focus of this study was not fatigue
McElhiney 2013 Main focus of this study was cognitive function
Mercadante 2001 Consecutive study, not randomised
Metz 2004 No randomisation
Moertel 1974 Single-blind study
Mohr 2003 Fatigue was not the primary outcome
Monk 2006 Open-label study
Moss 2006 Open-label study, case series
Popiela 1989 Single-blind study
Rabkin 2000a Investigators used pre-selection (“mood responders were maintained” after an open-label trial)
Rabkin 2011a This study was a subset of another study
Rammohan 2002 Phase II study
Romani 2004 Authors state that “Due to the design of the study, [the similarly decreased fatigue scores in both groups] cannot
be disjoined from a placebo effect.”
Roscoe 2005 Patients cannot be considered to be in a palliative care situation
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(Continued)
Sailer 2000 24 patients were assigned to 4 groups and patients were very heterogenous concerning disease duration
Shaw 2006 Phase II study
Shaw 2013 Phase II study
Spathis 2009 Open-label trial; aim of study was to determine feasibility of conducting a RCT for fatigue in lung cancer
Stockler 2007 Fatigue was studied as secondary outcome
Torta 2007 Main focus was depression. Fatigue was secondary outcome
Wade 2002 Investigators focus on disability, not fatigue
Wagner 1997 Open-label study, case series
Weitzner 2002 Fatigue was not the primary outcome
Wilwerding 1995 Focus was not fatigue, but narcotic-induced sedation
Zifko 2002 Open-label study
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Methylphenidate versus placebo in cancer
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FACIT-F score change 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Modafinil versus placebo in multiple sclerosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fatigue score change 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Pemoline versus placebo in multiple sclerosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fatigue score change 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Methylphenidate versus placebo in cancer, Outcome 1 FACIT-F score change.
Review: Pharmacological treatments for fatigue associated with palliative care
Comparison: 1 Methylphenidate versus placebo in cancer
Outcome: 1 FACIT-F score change
Study or subgroup Methylphenidate Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bruera 2006 52 9.6 (9.8) 53 7.5 (11.3) 0.20 [ -0.19, 0.58 ]
Butler 2007 20 6.5 (2.28) 21 2.8 (2.66) 1.46 [ 0.76, 2.16 ]
-2 -1 0 1 2
Favours placebo Favours methylphenidate
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Analysis 2.1. Comparison 2 Modafinil versus placebo in multiple sclerosis, Outcome 1 Fatigue score change.
Review: Pharmacological treatments for fatigue associated with palliative care
Comparison: 2 Modafinil versus placebo in multiple sclerosis
Outcome: 1 Fatigue score change
Study or subgroup Modafinil Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lange 2009 11 13 (7.7) 10 -0.4 (8.5) 1.59 [ 0.58, 2.60 ]
Stankoff 2005 56 8.7 (13.64) 59 13.7 (13.49) -0.37 [ -0.74, 0.00 ]
-2 -1 0 1 2
Favours placebo Favours modafinil
Analysis 3.1. Comparison 3 Pemoline versus placebo in multiple sclerosis, Outcome 1 Fatigue score change.
Review: Pharmacological treatments for fatigue associated with palliative care
Comparison: 3 Pemoline versus placebo in multiple sclerosis
Outcome: 1 Fatigue score change
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Krupp 1995 27 0.02 (0.2) 35 0.04 (0.2) -0.02 [ -0.12, 0.08 ]
Weinshenker 1992 23 7 (18) 18 -1 (16) 8.00 [ -2.43, 18.43 ]
-2 -1 0 1 2
Pemoline Placebo
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A D D I T I O N A L T A B L E S
Table 1. Drug treatment of fatigue: Populations, substances and outcome measures
Patient population Substance Outcome measures Study
Fatigue in advanced cancer Amphetamine BFI, McGill Quality of Life
Questionnaire, ECOG
Auret 2009
L-carnitine FACT-An, LASA, MMSE,
KPS
Cruciani 2009
L-carnitine BFI, FACIT-F, depression and
pain instrument
Cruciani 2012
Paroxetine FSC, MFI, Monopolar Profile
of Mood States
Morrow 2003
Methylphenidate FACIT-F, ESAS, daily diary Bruera 2006
Methylphenidate Cognitive function, FACIT-F,
CESD, MMSE, KPS
Butler 2007
Methylphenidate BFI, SED, SF-36 vitality sub-
scale, LASA, PSQI, SGIC
Moraska 2010
Methylphenidate BFI Roth 2010
Methylphenidate BFI Escalante 2014
Donepezil FACIT-F, ESAS Bruera 2007
Methylprednisolone NOSIE, LASA, Physician’s
Global
Della Cuna 1989
Modafinil BFI, ESS, POMS-DD Jean-Pierre 2010
Modafinil FACIT, ESS, HADS, QOL-
LAS
Spathis 2014
Fluoxetine FACT-G Fisch 2003
Standardised Mistletoe extract FACT-G Semiglazov 2006
Medroxyprogesterone acetate
(MPA)
FACT-G Simons 1996
Megestrol acetate EORTC-QLQ-C30
instrument
Westman 1999
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Table 1. Drug treatment of fatigue: Populations, substances and outcome measures (Continued)
Fatigue in amyotrophic lat-
eral sclerosis (ALS)
Modafinil CGI-E, FSS, ESS, BDI, RFS,
VAS
Rabkin 2009
Fatigue in HIV/AIDS Methylphenidate PFS Breitbart 2001
Pemoline PFS Breitbart 2001
Armodafinil CGI-I, FSS, HDRS, BDI Rabkin 2011
Modafinil CGI-I, FSS, HDRS, BDI
Amphetamine SCID; HDRS, BFI, BHS, VAS
for mood, CFS, VAS for energy
level
Wagner 2000
Testosterone CGIS “was expanded to include
ratings of energy, as well as
mood and a global rating. Sig-
nificant improvement was de-
fined as score of 1 or 2 on
CGIS”; HDRS, CFS
Rabkin 2004
Testosterone CGIS ratings for libido, mood,
energy and erectile function;
CFS
Rabkin 2000
Testosterone Body composition, muscle
strength and physical function,
MOS-30
Knapp 2008
Fluoxetine Body composition, muscle
strength and physical function,
MOS-30
Rabkin 2004
Fatigue in multiple sclerosis Pemoline VAS-F, KEDSS, mBDI; tol-
erance of adverse effects and
checklist to identify their nature
Weinshenker 1992
Pemoline FSS, MS Specific Fatigue Scale,
subjective response (verbal rat-
ing)
Krupp 1995
L-carnitine FSS, Fatigue Impact Scale, Beck
Depression Inventory, Social
Experience Checklist
Tomassini 2004
Amantadine FSS, Fatigue Impact Scale, Beck
Depression Inventory, Social
Experience Checklist
Tomassini 2004
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Table 1. Drug treatment of fatigue: Populations, substances and outcome measures (Continued)
Amantadine KEDSS; mBDI, “Stroop Inter-
ference Test” (attentional mea-
sure of freedom from distract-
ing information)
Cohen 1989
Amantadine KEDSS; mBDI, “Stroop Inter-
ference Test” (attentional mea-
sure of freedom from distract-
ing information)
Krupp 1995
Amantadine KEDSS Murray 1985
Amantadine KEDSS, patient preference Rosenberg 1988
Amantadine KEDSS; BDI; VAS-F Canadian MSRG 1987
Amantadine FSS Ashtari 2009
Amantadine FSS Shaygannejad 2012
Acetylsalicylic acid MFIS, KEDSS, CESD, SGIC,
FSS
Wingerchuk 2005
Acetylsalicylic acid FSS Shaygannejad 2012
Modafinil FSS, alertness test, NHPT,
TMS
Lange 2009
Modafinil MFIS, VAS-F, ESS Stankoff 2005
Modafinil FSS, VAS-F, FIS, SF-36 QOL Vasconcelos 2007
Dexamethasone FIS, QOL Yennurajalingam 2013
Alfacalcidol (Vit. D) FIS, QOL Barak 2014
End-stage renal
disease (ESRD)
L-carnitine KDQ Brass 2001
Parkinson’s disease Modafinil MFI, ESS, CESD Lou 2009
Multi-type advanced
disease (hospice
patients)
Methylphenidate PFS, VAS-F, ESAS Kerr 2012
End-stage COPD Paroxetine SF-36, chronic respiratory
questionnaire: 1 of 4 domains
was fatigue, geriatric depression
Lacasse 2004
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Table 1. Drug treatment of fatigue: Populations, substances and outcome measures (Continued)
scale
Postpolio syndrome Amantadine FSS Stein 1995
BDI = Beck Depression Inventory; BFI = Brief Fatigue Inventory; BHS = Beck Hopelessness Scale; CESD = Center for Epidemiologic
Studies Depression; CFS = Chalder Fatigue Scale; DB = double-blind; ECOG = performance status according to the Eastern
Cooperative Oncology Group Scale; EORTC-QLQ-C30 = European Organization for Research and Treatment of Cancer Quality
of Life Questionnaire; ESAS = Edmonton Symptom Assessment System; ESS = Epworth Sleepiness Scale; FACIT-F = Functional
Assessment for Chronic Illness Therapy - Fatigue; FACT-An = Functional Assessment of Cancer Therapy - Anaemia; FIS = Fatigue
Impact Scale; FSC = Fatigue Symptom Checklist; FSS = Fatigue Severity Scale; HADS = Hospital Anxiety and Depression Scale;
HDRS = Hamilton Depression Rating Scale; IM = intramuscular; ITT = intention-to-treat; IV = intravenous; KDQ = Kidney
Disease Questionnaire; KEDSS = Kurtzke Expanded Disability Status Scale; KPS = Karnofsky Performance Status; LASA = Linear
Analogue Scale Assessments; MAF = Multidimensional Assessment of Fatigue; mBDI = Modified Beck Depression Inventory; MFI
=Multidimensional Fatigue Inventory; MMSE =Mini Mental State Examination; MOS-30 =Medical Outcomes Study-Short Form
30;MPMM=Monopolar Profile ofMood States;MS =multiple sclerosis;MS SFS =Multiple Sclerosis Specific Fatigue Scale;NHPT
= Nine Hole Peg Test; NOSIE = Nurses’ Observational Scale for Inpatient Evaluation; NRS = numeric rating scale; PC = placebo-
controlled; PFS = Piper Fatigue Scale; PO = per oral; POMS-DD = Depression-Dejection subscale of the Profile of Mood States;
prn = as needed; PSQI = Pittsburgh Sleep Quality Index; pts = participants; QOL = RAYS quality of life; QOL-LAS = quality of life
linear analogue scale; RCT = randomised controlled trial; RFS = Role Function Scale; RT = radiation therapy; sc = subcutaneous;
SCID = depression according to Structured Clinical Interview for DSM-IV; SD = standard deviation; SE = standard error; SEC =
Social Experience Checklist; SED = Symptom Experience Diary; SF-36 = Short Form-36; SGIC = Subject Global Impression of
Change; TMS = transcranial magnetic Social Experience Checklist; VAS = visual analogue scale; VAS-F = visual analogue scale -
fatigue
Table 2. Overview of adverse reactions associated with fatigue treatment
Drug and indication Impact of adverse reaction Symptoms Study
Acetyl-L-carnitine and amanta-
dine in multiple sclerosis
1 (carnitine) and 5 (amanta-
dine) of 36 patients withdrew
Carnitine: insomnia, nervous-
ness
Amantadine: nausea, dizziness
Tomassini 2004
Amantadine in multiple sclero-
sis
7 of 32 reported adverse reac-
tions (versus 6 of 32 on placebo)
Hallucinations, nausea, gastric
irritation, early morning wak-
ening, hyperactivity, flu-like ill-
ness
Murray 1985
Amantadine in multiple sclero-
sis
- Constipation, nausea, anxiety,
influenza-like illness
Cohen 1989
Amantadine, pemoline in mul-
tiple sclerosis
No severe adverse reaction (did
not lead to withdrawal)
Pemoline: palpitations, nausea,
mood change, sleep distur-
bance, Amantadine: sleep dis-
turbance, palpitations
Krupp 1995
Dextroamphetamine
in HIV-positive men with fa-
tigue
None of 23 patients discontin-
ued during the 2 weeks of DB,
PC RCT
Overstimulation, heart palpi-
tation, sleep deprivation, loss
of appetite and/or weight,
Wagner 2000
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Table 2. Overview of adverse reactions associated with fatigue treatment (Continued)
headache. The authors reported
that adverse reactions generally
were “transient, reversible, and
well managed with dose reduc-
tion; no serious medical side ef-
fects were reported”
Dexamphetamine in advanced
cancer
Drop-out rate in verum group
compared to placebo group was
statistically not significant
Significant
increase in pulse rate. Transient
increase of dry mouth, insom-
nia, tremor, anorexia on days 6
and 8 (of 8)
Auret 2009
Pemoline in multiple sclerosis 3 of 46 dropped out because
of adverse reaction; 25% of pa-
tients did not tolerate pemoline
well according to the authors
Most common side effects were
anorexia, irritability, “jitteri-
ness” and insomnia
Weinshenker 1992
Acetylsalicylic acid in multiple
sclerosis
No serious adverse reaction Nausea, transient epigastric
pain (nausea, headache and di-
arrhoea occurred with placebo)
Wingerchuk 2005
Methylphenidate and pemoline
in HIV
Severe side effects relatively un-
common; 5 withdrew (2 on
methylphenidate, 2 on pemo-
line, 1 on placebo)
Hyperactivity, jitteriness, dry
mouth, rapid heart beat, dif-
ficulty sleeping, constipation,
neuropathic pain (1 patient)
Breitbart 2001
Methylphenidate in advanced
cancer
No severe adverse effects Most pts reported insomnia,
anorexia, restless-
ness, behavioural change and
vertigo. Numbers in placebo
groups were similar
Bruera 2006
Donepezil in advanced cancer No severe adverse effects Most pts reported anorexia,
nausea, restlessness, dizziness,
behaviour change, vertigo
Bruera 2007
Amantadine in multiple sclero-
sis
No statistically significant dif-
ference in prevalence of adverse
events reporting
Most pts reported headache, in-
somnia, nausea, anxiety, dizzi-
ness, ataxia
Canadian MSRG 1987
Paroxetine in end-stage COPD Only 1 of 12 pts dropped out
because of adverse effects re-
lated to the drug
Somnolence was reported by
5 pts, constipation, nausea,
headache tremor were rated by
2 pts each
Lacasse 2004
Testosterone for HIV-positive
pts
3 of 46 pts discontinued be-
cause of adverse reactions
Acne, irritability, insomnia,
headache, nasal congestion
Rabkin 2000
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Table 2. Overview of adverse reactions associated with fatigue treatment (Continued)
Testosterone and fluoxetine in
HIV
- Fluoxetine: diarrhoea, nausea,
nonspecific discomfort
Testosterone: sleepi-
ness; all treatments: dry mouth,
sleepiness, loose bowels
Rabkin 2004
Modafinil for HIV
patients
- Treatment-emergent side ef-
fects were relatively uncommon
CD4 cell count did not show ei-
ther statistically or clinically sig-
nificant changes
Rabkin 2010
Armodafinil in HIV Armodafinil was well tolerated,
with few and transient adverse
events
The most common was
headache
Rabkin 2011
Amantadine in post-polio syn-
drome
- Insomnia was the commonest
reported adverse reaction; dry
mouth was noted by 1 patient
Stein 1995
L-carnitine in
end-stage renal
disease (ESRD)
No serious adverse event was
believed by the investigators to
be certainly or probably drug-
related
Flu syndrome, injection-site re-
action, pain, pharyngitis,
headache and hyper-
tension showed no difference in
frequency between L-carnitine
and placebo
Brass 2001
Methylphenidate in cancer No serious adverse effect Some pts experienced nausea,
vomiting, facial rash
Escalante 2014
Fluoxetine in cancer A total of 16 adverse events were
judged to be possibly due to the
treatment and 6 to taking the
placebo
Allergic reaction, cardiac ar-
rhythmia,
dyspnoea, headaches, dizziness,
mood change, myalgia, fever,
diarrhoea, abdominal pain
Jean-Pierre 2010
Methylphenidate in
cancer
There was a significant differ-
ence in self reported toxicities
(SED)
Increased levels of nervous-
ness and appetite loss in the
methylphenidate group
Moraska 2010
Methylphenidate in
cancer
No severe adverse reaction 4 (31%) men who started re-
ceiving methylphenidate had to
be discontinued from the study
due to increased blood pressure
Roth 2010
Medroxyprogesterone acetate
(MPA) in cancer
- Nausea and vomiting Simons 1996
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Table 2. Overview of adverse reactions associated with fatigue treatment (Continued)
Acetylsalicylic acid and amanta-
dine in multiple sclerosis
Acetylsalicylic acid and amanta-
dine are both well tolerated
The most common side effects
of acetylsalicylic acid were nau-
sea (n = 53) and transient epi-
gastric pain (n = 51). The most
common side effect of amanta-
dine was also nausea (n = 51)
Shaygannejad 2012
Modafinil in cancer Modafinil seemed tobewell tol-
erated
Most symptoms are nausea,
vomiting, anxiety and headache
Spathis 2014
Dexamethasone in multiple
sclerosis
2 adverse events were probably
related to study treatment
Pain grade 3 and vomiting grade
2
Yennurajalingam 2013
COPD = chronic obstructive pulmonary disease; DB = double-blind; PC = placebo-controlled; pts = participants RCT = randomised
controlled trial
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Subject search was run on 28 April 2014
# 1. NEOPLASMS
# 2. (neoplasm* or cancer* or carcinoma* or tumour* or tumor* or adenocarcinoma* or leukeni* or lymphoma* or malignan*)
:ti,ab,kw
# 3. MULTIPLE SCLEROSIS
# 4. “multiple sclerosis”:ti,ab,kw
# 5. AMYOTROPHIC LATERAL SCLEROSIS
# 6. “amyotrophic lateral sclerosis”:ti,ab,kw
# 7. ACQUIRED IMMUNODEFICIENCY SYNDROME
# 8. AIDS-RELATED COMPLEX
# 9. HIV
# 10. HIV WASTING SYNDROME
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(Continued)
# 11. “acquired immunodeficiency syndrome”:ti,ab,kw
# 12. “AIDS related complex”:ti,ab,kw
# 13. “HIV”:ti,ab,kw
# 14. “human immunodeficiency virus”:ti,ab,kw
# 15. LUNG DISEASES
# 16. PULMONARY DISEASE CHRONIC OBSTRUCTIVE
# 17. HEART DISEASES
# 18. “lung disease*” or “heart disease*” or “pulmonary disease*”
# 19. HEART FAILURE
# 20. “cardiac failure” or “heart failure”
# 21. “incurable disease*” or “incurable illness*”
# 22. ((terminal or advanced or progressive or “end stage” or end-stage) and (illness* or disease*))
# 23. BONE MARROW TRANSPLANTATION
# 24. (neutropeni* or neutropaeni*):ti,ab,kw
# 25. RADIOTHERAPY
# 26. (radioth* or radiat* or irradiat* or radiochemo* or chemotherapy*):ti,ab,kw
# 27. “bone marrow” NEAR transplant*
# 28. “bone-marrow” NEAR transplant*
# 29. (fatigue near/4 treatment) or (treated near/4 treated) or (fatigue near/4 therapy) or (fatigue near/4 intervention)
# 30. (asthenia near/4 treatment) or (treated near/4 treated) or (fatigue near/4 therapy) or (fatigue near/4 intervention)
# 31. ((tired* near/4 treatment) or (tired* near/4 treated) or (tired* near/4 therapy) or (treatment near/4 exhausted) or (exhausted
near/4 therapy) or (exhaustion near/4 therapy))
# 32. apathy or apathetic or lassitude or lethargy* or “feeling drained” or “feeling sleepy” or “feeling sluggish” or “feeling weak*”
# 33. (FATIGUE or cancer-related fatigue or cancer related fatigue):ti,ab,kw
# 34. tired* or weary or weariness or exhaustion or exhausted or lackluster or astheni* or asthenia*
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(Continued)
# 35. lack* NEAR/2 energy
# 36. lack* NEAR/2 vigour
# 37. lack* NEAR/2 vigor
# 38. loss NEAR/2 energy
# 39. loss NEAR/2 vigour
# 40. loss NEAR/2 vigor
# 41. lost NEAR/2 energy
# 42. lost NEAR/2 vigour
# 43. lost NEAR/2 vigor
# 44. palliati* or hospice or “end of life”
# 45. #1-#28/OR
# 46. #29-#44
# 47. #45 AND #46
# 48. dexamphetamine or dextroamphetamine
# 49. ANTIDEPRESSIVE AGENTS
# 50. ADRENERGIC UPTAKE INHIBITORS
# 51. glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or corti-
costeroids
# 52 Carnitine or L-carntine
# 53. modafinil
# 54. amantadine or donepezil or pemoline
# 55. Methylphenidate or d-threo-methylphenidate
# 56. paroxetine
# 57. Aspirin or acetylsalicylic acid
# 58. citalopram
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(Continued)
# 59. bupropion
# 60. testosteronecypionate
# 61. #48 - #60/OR
# 62. #47 AND #61
Appendix 2. MEDLINE search strategy
Subject search combined with the recommended study design filter was run on 28 April 2014 (using OVID)
# 1. exp Neoplasms/
# 2. (cancer* or malignan*).mp.
# 3. multiple sclerosis.af.
# 4. amyotrophic lateral sclerosis.af.
# 5. (sclerosis adj4 (amyotroph* or multiple)).mp.
# 6. exp acquired immune deficiency syndrome/
# 7. aids related complex.mp.
# 8. exp Human immunodeficiency virus/
# 9. (HIV or AIDS).mp.
# 10. bone marrow transplantation.mp.
# 11. radiotherapy.mp.
# 12. (carcinoma* or tumour* or adenocarcinoma* or leukeni* or leukaemi* or lymphoma* or tumor*).mp
# 13. (neutropeni$ or neutropaeni$).mp.
# 14. (radioth* or radiat* or irradiat* or radiochemo* or chemotherap*).mp
# 15. Lung Disorders.mp.
# 16. heart disorders.mp.
# 17. congestive heart failure.mp.
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(Continued)
# 18. cor pulmonale.mp.
# 19. cancer fatigue.mp.
# 20. (cancer-related fatigue or cancer related fatigue).mp.
# 21. exp FATIGUE/
# 22. (tired$ or weary or weariness or exhaustion or exhausted or lacklustred or ((astheni$ or asthenia$) and syndrome)).mp
# 23. ((lack$ or loss or lost) adj2 (energy or vigour or vigor)).mp
# 24. (apathy or apathetic or lassitude or letharg$ or (feeling adj3 (drained or sleepy or sluggish or weak$))).mp
# 25. ((advanced or terminal* or progressi* or end-stage or endstage or “endstage”) adj6 (disease or illness)).mp
# 26. palliati*.mp.
# 27. (dexamphetamine or dextroamphetamine).mp.
# 28. (methylphenidate or threo$methylphenidate or d-threo-methylphenidate).mp
# 29. donepezil.mp.
# 30. amantadine.mp.
# 31. (Carnitine or L-carntine).mp.
# 32. pemoline.mp.
# 33. modafinil.mp.
# 34. paroxetine.mp.
# 35. (testosteronecypionate or androgen).mp.
# 36. (acetylsalicylic acid or aspirin).mp.
# 37. fluoxetin.mp
# 38. citalopram.mp
# 39. (glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or
corticosteroids).mp
# 40. bupropion.mp.
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(Continued)
# 41. (anti depressant agents or anti depressive agents or Selective serotonin reuptake inhibitors).mp
# 42. random*.ti,ab.
# 43. factorial*.ti,ab.
# 44. (crossover* or cross over* or cross-over*).ti,ab.
# 45. placebo*.ti,ab.
# 46. (doubl* adj blind*).ti,ab.
# 47. (singl* adj blind*).ti,ab.
# 48. randomized controlled trial.mp.
# 49. assign*.ti,ab.
# 50. allocat*.ti,ab.
# 51. evaluation study*.ti,ab.
# 52. prospective study*.ti,ab.
# 53. comparative study*.ti,ab.
# 54. (animal* or nonhuman* or animal experiment*).ti,ab.
# 55. #1-#18/OR
# 56. #19-26/OR
# 57. #27-41/OR
# 58. #42-53/OR
# 59. #55 AND #56 AND #57 AND #58
# 60. #59 NOT #54
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Appendix 3. EMBASE search strategy
Subject search combined with the recommended study design filter was run on 28 April 2014
# 1. neoplasm/exp
# 2. (cancer* or malignan*)
# 3. ‘multiple sclerosis’/exp
# 4. ‘amyothropic lateral sclerosis’/exp
# 5. sclerosis (amyotroph*4 or multiple)
# 6. ((‘acquired immune deficiency syndrome’/exp) OR (‘aids related complex’/exp))
# 7. ‘Human immunodeficiency virus’/exp
# 8. (HIV or AIDS)
# 9. ‘lung disease’/exp
# 10. ‘heart disease’/exp
# 11. ‘cor pulmonale’/exp
# 12. ‘congestive heart failure’/exp
# 13. (neoplasm* or cancer* or carcinoma* or tumour* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or tumor*
or tumor* or malignan*):ti,ab
# 14. (neoplasm* or cancer* or carcinoma* or tumour* or adenocarcinoma* or leukemi* or leukaemi* or lymphoma* or tumor*
or tumor* or malignan*)/mj
# 15. (neutropeni* or neutropaeni*):ti,ab
# 16. (neutropeni* or neutropaeni*)/mj
# 17. RADIOTHERAPY/exp
# 18. (radioth* or radiat* or irradiat* or radiochemo* or chemotherapy*):ti,ab
# 19. (radioth* or radiat* or irradiat* or radiochemo* or chemotherapy*)/mj
# 20. ((‘bone marrow’ transplant*4) or (‘bone-marrow’ NEAR transplant*))
# 21. advanced or terminal*6 or progressi*6 or end-stage or endstage or ’end stage’ (disease or illness)
# 22. FATIGUE/exp
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(Continued)
# 23. (Fatigue or ‘cancer-related fatigue’ or ‘cancer related fatigue’):ab,py
# 24. ‘FATIGUE’:de
# 25. tired* or weary or weariness or exhaustion or exhausted or lackluster or (asteni* or asthenia*) and syndrome
# 26. loss OR lost OR lack*2 AND (energy OR vigour OR vigor)
# 27. apathy or apathetic or lassitude or lethargy* or (feeling (drained or sleepy or sluggish or weak*3))
# 28. palliati* or hospice or ‘end of life’
# 29. #1 - #12/OR
# 30. #13 - #21 /OR
# 31. #22- #28 /OR
# 32. #29 and #30 and #31
# 33. (dexamphetamine or dextroamphetamine):ti,ab
# 34. (methylphenidate or threomethylphenidate or d-threo-methylphenidate):ti,ab
# 35. Donepezil:ti,ab
# 36. amantadine:ti,ab
# 37. Carnitine or l-carnitine:ti,ab
# 38. Pemoline:ti,ab
# 39. Modafinil:ti,ab
# 40. Paroxetine:ti,ab
# 41. (testosteronecypionate or androgen):ti,ab
# 42. (acetylsalicylic acid or aspirin):ti,ab
# 43. fluoxetin:ti,ab
# 44. Citalopram:ti,ab
# 45. (glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or
corticosteroids):ti,ab
# 46. Bupropion:ti,ab
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(Continued)
# 47. (‘anti depressant agents’ or ‘anti depressive agents’ or ‘Selective serotonin reuptake inhibitors’):ti,ab
# 48. #33 - #47 / OR
# 49. #32 and #48
# 50. controll*:ti,ab
# 51. factorial:ti,ab
# 52. (crossover or ‘cross over’ or ‘cross-over’):ti,ab
# 53. placebo:ti,ab
# 54. ‘double blind’:ti,ab
# 55. ’single blind’:ti,ab
# 56. assign*:ti,ab
# 57. allocate*:ti,ab
# 58. ‘crossover procedure’
# 59. ‘DOUBLE-BLIND PROCEDURE’
# 60. ‘RANDOMIZED CONTROLLED TRIAL’
# 61. ‘SINGLE BLIND PROCEDURE’
# 62. ‘evaluation study’
# 63. ‘prospective study’
# 64. ‘comparative study’
# 65. ‘animal experiment’ OR ‘nonhuman experiment’
# 66. #50-#64/OR
# 67. #49 AND #66 AND ([adult]/lim OR [aged]/lim) AND [humans]/lim AND [embase]/lim
# 68. #67 NOT #65
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Appendix 4. PsycINFO search strategy
Subject search combined with the recommended study design filter was run on 28 April 2014 (using OVID).
# 1. exp Neoplasms/
# 2. (cancer* or malignan*).mp.
# 3. multiple sclerosis.af.
# 4. amyotrophic lateral sclerosis.af.
# 5. (sclerosis adj4 (amyotroph* or multiple)).mp.
# 6. exp acquired immune deficiency syndrome/
# 7. aids related complex.mp.
# 8. exp Human immunodeficiency virus/
# 9. (HIV or AIDS).mp.
# 10. bone marrow transplantation.mp.
# 11. radiotherapy.mp.
# 12. (cancinoma* or tumour* or adenocarcinoma* or leukeni* or leukaemi* or lymphoma* or tumor*).mp
# 13. (neutropeni$ or neutropaeni$).mp.
# 14. (radioth* or radiat* or irradiat* or radiochemo* or chemotherap*).mp
# 15. Lung Disorders.mp.
# 16. heart disorders.mp.
# 17. congestive heart failure.mp.
# 18. cor pulmonale.mp.
# 19. cancer fatigue.mp.
# 20. (cancer-related fatigue or cancer related fatigue).mp.
# 21. exp FATIGUE/
# 22. (tired$ or weary or weariness or exhaustion or exhausted or lacklustred or ((astheni$ or asthenia$) and syndrome)).mp
# 23. ((lack$ or loss or lost) adj2 (energy or vigour or vigor)).mp
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(Continued)
# 24. (apathy or apathetic or lassitude or letharg$ or (feeling adj3 (drained or sleepy or sluggish or weak$))).mp
# 25. ((advanced or terminal* or progressi* or end-stage or endstage or “endstage”) adj6 (disease or illness)).mp
# 26. palliati*.mp.
# 27. (dexamphetamine or dextroamphetamine).mp.
# 28. (methylphenidate or threo$methylphenidate or d-threo-methylphenidate).mp
# 29. donepezil.mp.
# 30. amantadine.mp.
# 31. (Carnitine or L-carntine).mp.
# 32. pemoline.mp.
# 33. modafinil.mp.
# 34. paroxetine.mp.
# 35. (testosteronecypionate or androgen).mp.
# 36. (acetylsalicylic acid or aspirin).mp.
# 37. fluoxetin.mp
# 38. citalopram.mp
# 39. (glucocorticoid or steroid or steroids or dexamethason or dexamethasone or methylprednisolone or corticosteroid or
corticosteroids).mp
# 40. bupropion.mp.
# 41. (anti depressant agents or anti depressive agents or Selective serotonin reuptake inhibitors).mp
# 42. random*.ti,ab.
# 43. factorial*.ti,ab.
# 44. (crossover* or cross over* or cross-over*).ti,ab.
# 45. placebo*.ti,ab.
# 46. (doubl* adj blind*).ti,ab.
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# 47. (singl* adj blind*).ti,ab.
# 48. randomized controlled trial.mp.
# 49. assign*.ti,ab.
# 50. allocat*.ti,ab.
# 51. evaluation study*.ti,ab.
# 52. prospective study*.ti,ab.
# 53. comparative study*.ti,ab.
# 54. (animal* or nonhuman* or animal experiment*).ti,ab.
# 55. #1-#18/OR
# 56. #19-26/OR
# 57. #27-41/OR
# 58. #42-53/OR
# 59. #55 AND #56 AND #57 AND #58
# 60. #59 NOT #54
WH A T ’ S N E W
Last assessed as up-to-date: 28 April 2014.
Date Event Description
27 May 2015 Amended Contact details amended.
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H I S T O R Y
Protocol first published: Issue 4, 2007
Review first published: Issue 11, 2010
Date Event Description
19 January 2015 New citation required and conclusions have changed This review updates the original review, ’Pharmacologi-
cal treatments for fatigue associated with palliative care’
(Peuckmann-Post 2011), and also incorporates ’Drug
therapy for the management of cancer-related fatigue’
(Minton 2010). The updated search strategy identified
20 additional studies suitable for inclusion
6 June 2014 New search has been performed We used an updated search strategy and included ’Risk
of bias’ tables in this update
5 November 2010 Amended Minor amendment to title - text was italicised on pub-
lication and update of contact details
7 November 2008 Amended Further RevMan 5 conversion changes.
13 August 2008 Amended Converted to new review format.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We modified the search strategy to match the inclusion criteria better and to prevent technical error. NNTB and NNTH calculations
were not possible, as the information required to calculate these indicators was not included in the papers.
This updated review also incorporates another Cochrane review, ’Drug therapy for the management of cancer-related fatigue’ (Minton
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Palliative Care; Amantadine [therapeutic use]; Benzhydryl Compounds [therapeutic use]; Carnitine [therapeutic use]; Central Nervous
System Stimulants [therapeutic use]; Chronic Disease; Fatigue [∗drug therapy; etiology]; Kidney Failure, Chronic [complications];
Methylphenidate [therapeutic use]; Multiple Sclerosis [complications]; Neoplasms [complications]; Pemoline [therapeutic use]; Ran-
domized Controlled Trials as Topic
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Adult; Humans
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